

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
<b>A</b>	<b>ALIMENTARY TRACT AND METABOLISM</b>	<b>338,06</b>	<b>3</b>	<b>4</b>	<b>333 888</b>	<b>8</b>	<b>4</b>
A01	STOMATOLOGICAL PREPARATIONS	17,42	3	22	2 026	8	-3
A01A	STOMATOLOGICAL PREPARATIONS	17,42	3	22	2 026	8	-3
A01AA	Caries prophylactic agents	15,20	3	28	819	7	24
A01AA01	sodium fluoride	15,20	3	28	791	7	30
A01AA03	olaflur	-	-	-	28	1	-47
A01AB	Antiinfectives for local oral treatment	2,20	8	-7	1 180	10	-7
A01AB03	chlorhexidine	1,93	6	-4	910	6	-2
A01AB11	various	0,27	22	-19	270	21	-20
A01AC	Corticosteroids for local oral treatment	-	-	-	0	-	-100
A01AC01	triamcinolone	-	-	-	0	-	-100
A01AD	Other agents for local oral treatment	0,02	0	-14	28	0	-43
A01AD02	benzydamine	0,02	0	-14	28	0	-43
A02	DRUGS FOR ACID RELATED DISORDERS	74,84	3	2	30 187	5	-2
A02A	ANTACIDS	2,26	1	1	3 853	1	5
A02AA	Magnesium compounds	0,07	23	-1	139	23	-1
A02AA04	magnesium hydroxide	0,07	23	-1	139	23	-1
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	2,20	0	1	3 713	0	5
A02AD01	ordinary salt combinations	2,20	0	1	3 713	0	5
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	72,57	3	2	26 334	5	-3
A02BA	H2-receptor antagonists	0,15	6	-9	501	7	-9
A02BA02	ranitidine	0,00	0	-85	0	0	-85
A02BA03	famotidine	0,15	6	-7	501	7	-9
A02BB	Prostaglandins	0,05	61	30	103	61	30
A02BB01	misoprostol	0,05	61	30	103	61	30
A02BC	Proton pump inhibitors	70,91	3	2	22 444	5	-5
A02BC01	omeprazole	8,18	1	-5	2 136	2	-11
A02BC02	pantoprazole	39,80	4	5	7 931	9	-1
A02BC03	lansoprazole	5,20	1	-5	892	1	-26
A02BC04	rabeprazole	1,67	1	5	953	1	3

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A02BC05	esomeprazole	16,06	2	2	10 532	3	-4
A02BD	Combinations for eradication of Helicobacter pylori	0,03	0	30	259	0	19
A02BD03	lansoprazole, metronidazole and amoxicillin	0,01	1	155	58	1	155
A02BD07	lansoprazole, amoxicillin and clarithromycin	0,02	0	3	202	0	3
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	1,43	10	8	3 026	8	7
A02BX02	sucralfate	0,42	25	19	683	24	19
A02BX13	alginic acid	1,02	3	4	2 343	3	4
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	2,69	10	0	5 366	47	-2
A03A	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	1,15	7	-2	1 726	21	-9
A03AB	Synthetic anticholinergics, quaternary ammonium compounds	0,05	84	2	384	84	3
A03AB02	glycopyrronium bromide	0,05	84	2	384	84	3
A03AX	Other drugs for functional gastrointestinal disorders	1,10	4	-2	1 342	3	-12
A03AX13	silicones	1,10	4	-2	1 153	3	-17
A03AX15	menthae piperitae aetheroleum	-	-	-	189	0	40
A03B	BELLADONNA AND DERIVATIVES, PLAIN	0,04	92	5	408	93	19
A03BA	Belladonna alkaloids, tertiary amines	0,04	92	6	341	92	20
A03BA01	atropine	0,04	92	6	341	92	20
A03BB	Belladonna alkaloids semisynthetic, quaternary ammonium compounds	0,00	94	-1	67	93	14
A03BB01	butylscopolamine	0,00	94	-1	67	93	14
A03C	ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS	0,17	1	-8	179	1	-8
A03CA	Synthetic anticholinergic agents in combination with psycholeptics	0,17	1	-8	179	1	-8
A03CA02	clidinium and psycholeptics	0,17	1	-8	179	1	-8
A03D	ANTISPASMODICS IN COMBINATION WITH ANALGESICS	0,30	10	8	2 516	66	-3
A03DA	Synthetic anticholinergic agents in combination with analgesics	0,30	10	8	2 516	66	-3
A03DA02	pitofenone and analgesics	0,30	10	8	2 516	66	-3

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A03F	PROPULSIVES	1,02	10	1	538	28	28
A03FA	Propulsives	1,02	10	1	538	28	28
A03FA01	metoclopramide	1,02	10	1	538	28	28
A04	ANTIEMETICS AND ANTINAUSEANTS	0,30	42	-1	5 605	54	15
A04A	ANTIEMETICS AND ANTINAUSEANTS	0,30	42	-1	5 605	54	15
A04AA	Serotonin (5HT3) antagonists	0,24	46	-1	4 738	55	15
A04AA01	ondansetron	0,18	47	12	2 601	73	40
A04AA02	granisetron	0,04	48	-31	655	49	-23
A04AA05	palonosetron	0,00	100	-50	227	100	-12
A04AA55	palonosetron, combinations	0,01	13	13	1 256	13	8
A04AD	Other antiemetics	0,06	27	1	867	46	19
A04AD01	scopolamine	0,06	24	2	535	24	43
A04AD12	aprepitant	0,01	61	-9	333	81	-7
A05	BILE AND LIVER THERAPY	1,03	2	11	1 603	2	13
A05A	BILE THERAPY	1,03	2	11	1 603	2	13
A05AA	Bile acids and derivatives	1,03	2	11	1 603	2	13
A05AA02	ursodeoxycholic acid	1,03	2	11	1 339	2	0
A05AA04	obeticholic acid	0,00	0	344	264	0	267
A06	DRUGS FOR CONSTIPATION	53,37	7	4	30 270	10	4
A06A	DRUGS FOR CONSTIPATION	53,37	7	4	30 270	10	4
A06AB	Contact laxatives	6,01	5	-5	3 510	7	-6
A06AB02	bisacodyl	0,66	1	-7	248	1	-6
A06AB06	senna glycosides	0,12	0	-2	51	0	-2
A06AB08	sodium picosulfate	5,22	5	-5	2 572	4	-9
A06AB56	senna glycosides, combinations	-	-	-	145	0	-11
A06AB58	sodium picosulfate, combinations	0,00	28	12	493	28	12
A06AC	Bulk-forming laxatives	12,87	0	7	6 270	2	7
A06AC01	ispaghula (psylla seeds)	12,31	0	8	6 051	2	7
A06AC51	ispaghula, combinations	0,56	1	-5	220	1	-4
A06AD	Osmotically acting laxatives	33,00	10	5	17 043	12	6
A06AD11	lactulose	12,78	9	-3	2 560	8	-3
A06AD15	macrogol	19,29	11	12	12 806	11	9
A06AD17	sodium phosphate	-	-	-	26	26	-38
A06AD65	macrogol, combinations	0,93	3	-14	1 651	22	-4

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A06AG	Enemas	1,30	10	-1	2 421	17	0
A06AG02	bisacodyl	0,24	31	-1	411	30	-1
A06AG10	docusate sodium, incl. combinations	0,06	49	2	566	45	2
A06AG11	laurilsulfate, incl. combinations	1,00	2	-1	1 443	2	0
A06AH	Peripheral opioid receptor antagonists	0,14	26	2	773	37	2
A06AH01	methylnaltrexone bromide	0,00	97	4	137	97	4
A06AH03	naloxegol	0,13	24	2	636	24	2
A06AX	Other drugs for constipation	0,06	8	9	251	9	8
A06AX04	linaclotide	0,03	1	8	120	1	8
A06AX05	prucalopride	0,03	16	10	131	16	8
A07	ANTIDIARRHEALS, INTESTINAL	13,64	2	-2	29 644	5	2
	ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS						
A07A	INTESTINAL ANTIINFECTIVES	0,20	19	16	3 060	32	15
A07AA	Antibiotics	0,20	19	16	3 060	32	15
A07AA02	nystatin	0,07	18	5	648	18	-5
A07AA09	vancomycin	0,01	47	6	722	47	5
A07AA11	rifaximin	0,12	18	26	1 293	18	26
A07AA12	fidaxomicin	0,00	72	45	397	72	45
A07B	INTESTINAL ADSORBENTS	0,12	54	-9	597	52	-11
A07BA	Charcoal preparations	0,12	54	-9	597	52	-11
A07BA01	medicinal charcoal	0,12	54	-9	597	52	-11
A07C	ELECTROLYTES WITH CARBOHYDRATES	0,01	5	4	143	5	4
A07CA	Oral rehydration salt formulations	0,01	5	4	143	5	4
A07D	ANTIPROPULSIVES	1,22	2	2	3 919	1	3
A07DA	Antipropulsives	1,22	2	2	3 919	1	3
A07DA02	opium	0,00	0	-	0	0	-
A07DA03	loperamide	1,22	2	2	3 116	1	5
A07DA53	loperamide, combinations	-	-	-	804	0	-3
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS	11,30	1	-3	19 289	1	2
A07EA	Corticosteroids acting locally	0,36	3	-48	2 084	3	5
A07EA06	budesonide	0,36	3	-48	2 084	3	5
A07EC	Aminosalicylic acid and similar agents	10,94	1	0	17 205	1	1
A07EC01	sulfasalazine	3,16	1	-3	2 847	1	-3
A07EC02	mesalazine	7,77	1	2	14 341	1	2

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A07EC03	olsalazine	0,01	2	15	16	2	15
A07F	ANTIDIARRHEAL MICROORGANISMS	0,79	4	-4	2 374	4	-4
A07FA	Antidiarrheal microorganisms	0,79	4	-4	2 374	4	-4
A07FA02	saccharomyces boulardii	0,79	4	-4	2 374	4	-4
A07X	OTHER ANTIDIARRHEALS	-	-	-	261	7	-13
A07XA	Other antidiarrheals	-	-	-	261	7	-13
A07XA04	racecadotril	-	-	-	261	7	-13
A08	ANTI Obesity PREPARATIONS, EXCL. DIET PRODUCTS	0,07	0	-2	608	0	1
A08A	ANTI Obesity PREPARATIONS, EXCL. DIET PRODUCTS	0,07	0	-2	608	0	1
A08AA	Centrally acting antiobesity products	-	-	-	337	0	1
A08AA62	bupropion and naltrexone	-	-	-	337	0	1
A08AB	Peripherally acting antiobesity products	0,07	0	-2	270	0	1
A08AB01	orlistat	0,07	0	-2	270	0	1
A09	DIGESTIVES, INCL. ENZYMES	1,32	3	-21	3 343	3	6
A09A	DIGESTIVES, INCL. ENZYMES	1,32	3	-21	3 343	3	6
A09AA	Enzyme preparations	1,32	3	-21	3 343	3	6
A09AA02	multienzymes (lipase, protease etc.)	1,32	3	-21	3 343	3	6
A10	DRUGS USED IN DIABETES	109,10	2	3	180 754	2	6
A10A	INSULINS AND ANALOGUES	30,19	3	-3	54 666	2	-6
A10AB	Insulins and analogues for injection, fast-acting	10,71	3	1	13 752	3	-10
A10AB01	insulin (human)	0,05	38	-17	59	38	-16
A10AB04	insulin lispro	1,51	1	-3	1 703	1	-4
A10AB05	insulin aspart	8,66	3	2	11 264	3	-12
A10AB06	insulin glulisine	0,49	2	-1	725	2	-3
A10AC	Insulins and analogues, intermediate-acting	0,47	13	-10	665	13	-10
A10AC01	insulin (human)	0,47	13	-10	665	13	-10
A10AD	Insulins and analogues, intermediate-acting combined with fast-acting	0,22	5	-24	354	5	-24
A10AD04	insulin lispro	0,01	3	-25	19	3	-25
A10AD05	insulin aspart	0,20	5	-24	335	5	-24
A10AE	Insulins and analogues, long-acting	18,80	2	-5	39 896	2	-5
A10AE04	insulin glargine	11,44	2	-7	22 876	2	-7

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A10AE05	insulin detemir	3,56	3	-19	7 930	3	-19
A10AE06	insulin degludec	3,79	2	21	9 089	2	21
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	78,91	1	6	126 089	1	12
A10BA	Biguanides	34,42	1	2	11 231	1	-1
A10BA02	metformin	34,42	1	2	11 231	1	-1
A10BB	Sulfonylureas	0,69	1	-21	69	2	-21
A10BB12	glimepiride	0,69	1	-21	69	2	-21
A10BD	Combinations of oral blood glucose lowering drugs	6,19	1	-1	13 372	1	-2
A10BD07	metformin and sitagliptin	3,79	1	-7	7 670	1	-9
A10BD08	metformin and vildagliptin	0,49	0	-11	1 085	0	-11
A10BD09	pioglitazone and alogliptin	0,01	1	13	20	1	13
A10BD10	metformin and saxagliptin	0,01	0	-18	28	0	-18
A10BD11	metformin and linagliptin	0,21	1	-2	460	1	-2
A10BD13	metformin and alogliptin	-	-	-100	0	-	-100
A10BD15	metformin and dapagliflozin	0,60	0	18	1 377	0	19
A10BD19	linagliptin and empagliflozin	0,07	1	3	299	1	3
A10BD20	metformin and empagliflozin	1,01	0	20	2 371	0	20
A10BD21	saxagliptin and dapagliflozin	0,01	0	16	44	0	16
A10BD23	metformin and ertugliflozin	0,00	0	76	4	0	74
A10BD24	sitagliptin and ertugliflozin	0,00	0	103	14	0	104
A10BG	Thiazolidinediones	0,47	1	-8	667	1	-6
A10BG03	pioglitazone	0,47	1	-8	667	1	-6
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors	12,52	2	-1	26 638	3	-2
A10BH01	sitagliptin	6,86	2	-8	14 910	2	-8
A10BH02	vildagliptin	0,76	2	-13	1 558	2	-13
A10BH03	saxagliptin	0,04	2	-13	95	2	-12
A10BH04	alogliptin	0,03	0	-9	58	0	-6
A10BH05	linagliptin	4,84	3	12	10 019	3	12
A10BJ	Glucagon-like peptide-1 (GLP-1) analogues	11,10	1	15	41 474	1	26
A10BJ01	exenatide	0,28	1	-94	1 481	1	-29
A10BJ02	liraglutide	1,40	1	-21	8 755	1	-28
A10BJ03	lixisenatide	0,00	0	-73	6	0	-73
A10BJ05	dulaglutide	0,75	1	-4	3 429	1	-9

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A10BJ06	semaglutide	8,67	0	248	27 804	1	87
A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors	13,39	1	22	32 564	1	22
A10BK01	dapagliflozin	4,38	1	23	10 482	1	25
A10BK02	canagliflozin	0,36	0	87	1 057	1	85
A10BK03	empagliflozin	8,63	1	20	20 982	1	18
A10BK04	ertugliflozin	0,02	1	35	43	1	36
A10BX	Other blood glucose lowering drugs, excl. insulins	0,12	1	-14	74	1	-12
A10BX02	repaglinide	0,12	1	-14	74	1	-12
A11	VITAMINS	22,60	3	10	7 081	19	-24
A11C	VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO	10,22	1	68	1 608	1	54
A11CC	Vitamin D and analogues	10,22	1	68	1 608	1	54
A11CC02	dihydrotachysterol	-	-	-100	0	-	-100
A11CC03	alfacalcidol	0,50	3	10	476	3	10
A11CC05	colecalfiferol (vitamin D3)	9,72	1	73	1 133	0	92
A11D	VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12	4,27	13	-8	2 184	58	-3
A11DA	Vitamin B1, plain	0,48	99	-4	1 276	99	5
A11DA01	thiamine (vit B1)	0,48	99	-4	1 276	99	5
A11DB	Vitamin B1 in comb. with vitamin B6 and/or vitamin B12	3,79	2	-9	908	2	-13
A11E	VITAMIN B-COMPLEX, INCL. COMBINATIONS	6,57	2	-12	2 978	1	-48
A11EA	Vitamin B-complex	2,59	4	-1	983	4	-1
A11EX	Vitamin B-complex, other combinations	3,97	0	-18	1 996	0	-58
A11G	ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS	1,33	0	-35	89	0	-35
A11GA	Ascorbic acid (vit C), plain	1,33	0	-35	89	0	-35
A11GA01	ascorbic acid (vit C)	1,33	0	-35	89	0	-35
A11H	OTHER PLAIN VITAMIN PREPARATIONS	0,21	7	-2	221	4	-3
A11HA	Other plain vitamin preparations	0,21	7	-2	221	4	-3
A11HA02	pyridoxine (vit B6)	0,14	11	2	44	11	2
A11HA03	tocopherol (vit E)	0,07	1	-7	17	1	-7
A11HA08	tocofersolan	0,00	100	-53	1	100	-53

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A11HA30	dexpanthenol	-	-	-	160	1	-2
A12	MINERAL SUPPLEMENTS	41,64	3	3	16 546	4	1
A12A	CALCIUM	35,38	2	3	11 312	2	-1
A12AA	Calcium	1,13	1	0	846	1	-1
A12AA04	calcium carbonate	1,13	1	0	846	1	0
A12AA06	calcium lactate gluconate	-	-	-100	0	-	-100
A12AX	Calcium, combinations with vitamin D and/or other drugs	34,25	2	3	10 466	2	-1
A12B	POTASSIUM	6,21	7	3	5 190	8	4
A12BA	Potassium	6,21	7	3	5 190	8	4
A12BA01	potassium chloride	6,21	7	3	5 190	8	4
A12C	OTHER MINERAL SUPPLEMENTS	0,06	31	-48	44	31	-48
A12CA	Sodium	0,06	31	-48	44	31	-48
A12CA01	sodium chloride	0,06	31	-48	44	31	-48
A14	ANABOLIC AGENTS FOR SYSTEMIC USE	0,02	20	5	13	20	5
A14A	ANABOLIC STEROIDS	0,02	20	5	13	20	5
A14AB	Estren derivatives	0,02	20	5	13	20	5
A14AB01	nandrolone	0,02	20	5	13	20	5
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	0,03	36	-11	20 842	45	14
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	0,03	36	-11	20 842	45	14
A16AA	Amino acids and derivatives	0,00	67	18	211	87	30
A16AA04	mercaptamine	0,00	0	-4	21	0	-4
A16AA05	carglumic acid	0,00	100	24	183	100	36
A16AA06	betaine	0,00	6	31	8	6	31
A16AB	Enzymes	0,01	41	-26	15 373	47	15
A16AB02	imiglucerase	0,00	42	21	758	42	15
A16AB03	agalsidase alfa	0,00	31	-17	1 372	31	-18
A16AB04	agalsidase beta	0,01	39	6	9 533	39	3
A16AB05	laronidase	0,00	100	2	263	100	2
A16AB07	alglucosidase alfa	0,00	100	-95	663	100	7
A16AB09	idursulfase	-	-	-	219	100	-
A16AB10	velaglucerase alfa	0,00	0	-8	855	0	-11



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A16AB13	asfotase alfa	-	-	-	202	0	-
A16AB14	sebelipase alfa	0,00	100	-	1 509	100	-
A16AX	Various alimentary tract and metabolism products	0,01	26	10	5 258	37	13
A16AX03	sodium phenylbutyrate	0,00	4	8	238	4	8
A16AX04	nitisinone	0,00	0	8	487	0	-4
A16AX05	zinc acetate	0,00	100	33	2	100	33
A16AX06	miglustat	0,00	0	61	375	0	59
A16AX08	teduglutide	0,00	100	115	1 283	100	108
A16AX09	glycerol phenylbutyrate	0,00	1	12	196	1	12
A16AX10	eliglustat	0,00	0	12	1 211	0	9
A16AX12	trientine	0,00	100	36	657	100	35
A16AX14	migalastat	0,00	0	-34	793	0	-35
A16AX15	telotristat	0,00	83	-75	15	83	-75
<b>B</b>	<b>BLOOD AND BLOOD FORMING ORGANS</b>	<b>146,18</b>	<b>4</b>	<b>4</b>	<b>296 173</b>	<b>25</b>	<b>4</b>
B01	ANTITHROMBOTIC AGENTS	116,93	3	1	162 739	10	5
B01A	ANTITHROMBOTIC AGENTS	116,93	3	1	162 739	10	5
B01AA	Vitamin K antagonists	6,76	1	-17	1 547	2	-18
B01AA03	warfarin	6,76	1	-17	1 547	2	-18
B01AB	Heparin group	5,78	34	-12	19 529	38	-16
B01AB01	heparin	0,07	99	-6	736	99	-10
B01AB02	antithrombin	0,00	100	-7	356	100	-7
B01AB04	dalteparin	0,63	16	31	1 612	18	27
B01AB05	enoxaparin	3,52	41	-29	7 945	42	-45
B01AB09	danaparoid	0,00	100	61	238	100	49
B01AB10	tinzaparin	1,56	22	47	8 642	28	42
B01AC	Platelet aggregation inhibitors excl. heparin	77,53	2	0	19 719	6	-3
B01AC04	clopidogrel	10,84	3	5	1 569	19	0
B01AC06	acetylsalicylic acid	62,22	1	0	7 383	1	1
B01AC07	dipyridamole	0,11	2	-40	92	2	-41
B01AC11	iloprost	0,00	66	-58	176	45	-31
B01AC13	abciximab	-	-	-100	0	-	-100
B01AC16	eptifibatide	0,00	100	24	112	100	25
B01AC17	tirofiban	0,00	100	-14	23	100	-14
B01AC21	treprostinil	0,00	3	-24	1 558	3	-28

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B01AC22	prasugrel	0,04	11	27	146	11	23
B01AC24	ticagrelor	0,81	4	-5	3 343	4	-6
B01AC25	cangrelor	0,00	100	31	193	100	31
B01AC27	selexipag	0,00	1	29	1 142	2	45
B01AC30	combinations	3,51	2	-6	3 982	2	-6
B01AD	Enzymes	0,00	100	-15	4 700	100	-7
B01AD02	alteplase	0,00	100	1	4 207	100	3
B01AD11	tenecteplase	0,00	99	-49	493	99	-49
B01AE	Direct thrombin inhibitors	2,74	2	-5	12 032	4	-5
B01AE03	argatroban	0,00	100	-8	78	100	-7
B01AE06	bivalirudin	0,00	100	41	147	100	41
B01AE07	dabigatran etexilate	2,74	2	-5	11 808	2	-5
B01AF	Direct factor Xa inhibitors	24,11	2	15	104 249	2	14
B01AF01	rivaroxaban	9,72	2	7	40 303	2	7
B01AF02	apixaban	12,86	2	21	56 798	3	19
B01AF03	edoxaban	1,53	2	23	7 149	3	23
B01AX	Other antithrombotic agents	0,02	19	-12	963	77	-21
B01AX01	defibrotide	0,00	86	-17	592	86	-17
B01AX05	fondaparinux	0,02	18	-12	166	18	-14
B01AX07	caplacizumab	0,00	100	-33	205	100	-33
B02	ANTIHEMORRHAGICS	0,38	20	12	54 564	27	-1
B02A	ANTIFIBRINOLYTICS	0,31	17	15	2 011	69	-11
B02AA	Amino acids	0,31	16	15	1 742	65	-14
B02AA02	tranexamic acid	0,31	16	15	1 742	65	-14
B02AB	Proteinase inhibitors	0,00	100	11	268	100	7
B02AB01	aprotinin	0,00	100	14	217	100	14
B02AB02	alfa1 antitrypsin	0,00	100	-15	51	100	-15
B02B	VITAMIN K AND OTHER HEMOSTATICS	0,07	36	0	52 554	26	-1
B02BA	Vitamin K	0,02	89	-6	115	87	-2
B02BA01	phytomenadione	0,02	89	-6	115	87	-2
B02BB	Fibrinogen	0,00	100	6	1 993	100	7
B02BB01	fibrinogen, human	0,00	100	6	1 993	100	7
B02BC	Local hemostatics	-	-	-	3 304	100	4
B02BC30	combinations	-	-	-	3 304	100	4

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B02BD	Blood coagulation factors	-	-	-	38 247	19	-4
B02BD01	coagulation factor IX, II, VII and X in combination	-	-	-	3 946	100	-11
B02BD02	coagulation factor VIII	-	-	-	23 854	3	-1
B02BD03	factor VIII inhibitor bypassing activity	-	-	-	602	100	-28
B02BD04	coagulation factor IX	-	-	-	5 437	8	0
B02BD06	von Willebrand factor and coagulation factor VIII in combination	-	-	-	2 861	22	-26
B02BD07	coagulation factor XIII	-	-	-	779	35	7
B02BD08	coagulation factor VIIa	-	-	-	488	72	1
B02BD10	von Willebrand factor	-	-	-	280	59	440
B02BX	Other systemic hemostatics	0,05	14	3	8 894	10	16
B02BX04	romiplostim	0,02	18	16	1 978	18	10
B02BX05	eltrombopag	0,03	12	-6	4 008	12	-11
B02BX06	emicizumab	0,00	1	174	2 907	1	112
B02BX08	avatrombopag	0,00	100	-	1	100	-
B03	ANTIANEMIC PREPARATIONS	28,86	5	19	36 829	45	3
B03A	IRON PREPARATIONS	5,59	6	-6	18 096	83	10
B03AA	Iron bivalent, oral preparations	3,85	3	-7	1 710	3	-27
B03AA01	ferrous glycine sulfate	3,00	3	-7	1 358	3	-29
B03AA07	ferrous sulfate	0,85	2	-5	352	2	-18
B03AB	Iron trivalent, oral preparations	1,54	2	-6	1 283	3	-5
B03AB05	ferric oxide polymaltose complexes	1,53	2	-6	1 273	3	-5
B03AB10	ferric maltol	0,00	0	75	10	0	75
B03AC	Iron, parenteral preparations	0,20	99	16	15 103	98	19
B03B	VITAMIN B12 AND FOLIC ACID	22,00	5	28	2 585	5	19
B03BA	Vitamin B12 (cyanocobalamin and derivatives)	5,96	5	5	1 223	4	12
B03BA01	cyanocobalamin	1,59	1	44	531	1	44
B03BA03	hydroxocobalamin	4,37	7	-5	692	7	-5
B03BB	Folic acid, combinations	16,05	5	40	1 363	6	26
B03BB01	folic acid	16,05	5	40	1 363	6	26
B03X	OTHER ANTIANEMIC PREPARATIONS	1,27	10	3	16 147	10	-5
B03XA	Other antianemic preparations	1,27	10	3	16 147	10	-5
B03XA01	erythropoietin	0,23	19	5	2 335	20	-4
B03XA02	darbepoetin alfa	0,89	9	4	11 880	9	-4

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B03XA03	methoxy polyethylene glycolepoetin beta	0,16	7	-5	1 933	7	-13
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS	-	-	-	30 685	81	0
B05A	BLOOD AND RELATED PRODUCTS	-	-	-	5 959	100	3
B05AA	Blood substitutes and plasma protein fractions	-	-	-	5 959	100	3
B05AA01	albumin	-	-	-	5 950	100	3
B05AA06	gelatin agents	-	-	-	9	98	-25
B05AA07	hydroxyethylstarch	-	-	-	0	-	-100
B05B	I.V. SOLUTIONS	-	-	-	17 316	99	0
B05BA	Solutions for parenteral nutrition	-	-	-	5 341	100	-2
B05BA01	amino acids	-	-	-	93	100	19
B05BA02	fat emulsions	-	-	-	50	99	27
B05BA03	carbohydrates	-	-	-	431	99	-3
B05BA10	combinations	-	-	-	4 767	100	-2
B05BB	Solutions affecting the electrolyte balance	-	-	-	11 950	99	1
B05BB01	electrolytes	-	-	-	11 134	99	1
B05BB02	electrolytes with carbohydrates	-	-	-	815	100	-1
B05BC	Solutions producing osmotic diuresis	-	-	-	25	97	-21
B05BC01	mannitol	-	-	-	25	97	-21
B05D	PERITONEAL DIALYTICS	-	-	-	5 962	6	-3
B05DA	Isotonic solutions	-	-	-	2 566	5	4
B05DB	Hypertonic solutions	-	-	-	3 395	6	-7
B05X	I.V. SOLUTION ADDITIVES	-	-	-	1 207	98	0
B05XA	Electrolyte solutions	-	-	-	795	97	1
B05XA01	potassium chloride	-	-	-	232	98	0
B05XA03	sodium chloride	-	-	-	130	90	-1
B05XA05	magnesium sulfate	-	-	-	99	100	-7
B05XA06	potassium phosphate, incl. comb. with other potassium salts	-	-	-	30	99	-13
B05XA07	calcium chloride	-	-	-	53	100	92
B05XA14	sodium glycerophosphate	-	-	-	57	95	-2
B05XA31	electrolytes in combination with other drugs	-	-	-	195	100	-1
B05XB	Amino acids	-	-	-	21	100	-21
B05XB02	alanyl glutamine	-	-	-	21	100	-21

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B05XC	Vitamins	-	-	-	390	100	-2
B05Z	HEMODIALYTICS AND HEMOFILTRATES	-	-	-	242	100	0
B05ZB	Hemofiltrates	-	-	-	242	100	0
B06	OTHER HEMATOLOGICAL AGENTS	0,01	15	92	11 356	13	41
B06A	OTHER HEMATOLOGICAL AGENTS	0,01	15	92	11 356	13	41
B06AB	Heme products	-	-	-	43	100	183
B06AB01	hemin	-	-	-	43	100	183
B06AC	Drugs used in hereditary angioedema	0,00	10	82	11 229	12	39
B06AC01	c1-inhibitor, plasma derived	0,00	16	-13	3 712	16	-16
B06AC02	icatibant	0,00	6	88	2 661	9	31
B06AC04	conestat alfa	0,00	100	7	100	100	4
B06AC05	lanadelumab	0,00	8	252	4 756	9	216
B06AX	Other hematological agents	0,00	100	-	84	100	-
B06AX01	crizanlizumab	0,00	100	-	84	100	-
<b>C</b>	<b>CARDIOVASCULAR SYSTEM</b>	<b>682,40</b>	<b>2</b>	<b>4</b>	<b>130 666</b>	<b>13</b>	<b>-5</b>
C01	CARDIAC THERAPY	12,91	10	-1	21 173	61	-6
C01A	CARDIAC GLYCOSIDES	1,79	5	-6	1 052	19	0
C01AA	Digitalis glycosides	1,79	5	-6	1 052	19	0
C01AA05	digoxin	1,79	5	-6	1 052	19	0
C01B	ANTIARRHYTHMICS, CLASS I AND III	1,92	4	-2	2 512	38	-12
C01BB	Antiarrhythmics, class IB	0,00	98	-42	165	98	-42
C01BB01	lidocaine	0,00	98	-42	165	98	-42
C01BC	Antiarrhythmics, class IC	1,36	1	-3	1 145	2	-3
C01BC04	flecainide	1,36	1	-3	1 145	2	-3
C01BD	Antiarrhythmics, class III	0,56	10	-1	550	21	-18
C01BD01	amiodarone	0,45	12	-1	255	26	-2
C01BD05	ibutilide	0,00	100	-38	48	100	-37
C01BD07	dronedarone	0,11	1	-1	247	1	-26
C01BG	Other antiarrhythmics, class I and III	0,00	100	-11	652	100	-11
C01BG11	vernakalant	0,00	100	-11	652	100	-11
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0,78	87	12	12 026	83	-9
C01CA	Adrenergic and dopaminergic agents	0,77	87	13	7 486	73	-8
C01CA01	etilefrine	0,05	26	-25	301	73	16

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C01CA02	isoprenaline	0,00	100	203	416	100	203
C01CA03	norepinephrine	0,05	99	-39	1 304	99	-43
C01CA04	dopamine	0,00	80	-67	42	81	-70
C01CA06	phenylephrine	0,02	100	9	637	100	-6
C01CA07	dobutamine	0,00	100	-55	40	100	-55
C01CA17	midodrine	0,01	16	24	84	18	30
C01CA24	epinephrine	0,65	91	26	4 379	59	5
C01CA26	ephedrine	-	-	-	283	98	-2
C01CE	Phosphodiesterase inhibitors	0,00	100	-23	633	100	-23
C01CE02	milrinone	0,00	100	-23	633	100	-23
C01CX	Other cardiac stimulants	0,00	100	-10	3 906	100	-10
C01CX08	levosimendan	0,00	100	-10	3 906	100	-10
C01D	VASODILATORS USED IN CARDIAC DISEASES	8,38	5	-1	4 631	16	2
C01DA	Organic nitrates	8,38	5	-1	4 630	16	2
C01DA02	glyceryl trinitrate	0,60	24	7	1 176	53	16
C01DA08	isosorbide dinitrate	1,41	6	19	927	7	-6
C01DA14	isosorbide mononitrate	6,37	3	-5	2 527	3	-1
C01DX	Other vasodilators used in cardiac diseases	-	-	-	0	0	-
C01DX22	vericiguat	-	-	-	0	0	-
C01E	OTHER CARDIAC PREPARATIONS	0,04	59	37	954	96	34
C01EA	Prostaglandins	0,00	100	6	331	100	15
C01EA01	alprostadil	0,00	100	6	331	100	15
C01EB	Other cardiac preparations	0,04	59	38	622	94	46
C01EB10	adenosine	0,02	98	73	364	98	64
C01EB16	ibuprofen	0,00	100	32	12	100	32
C01EB17	ivabradine	0,02	4	9	34	5	3
C01EB21	regadenoson	0,00	100	31	212	100	31
C02	ANTIHYPERTENSIVES	3,32	3	5	9 158	7	0
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	2,70	2	4	1 571	25	3
C02AC	Imidazoline receptor agonists	2,70	2	4	1 571	25	3
C02AC01	clonidine	0,06	34	-6	355	87	-23
C02AC02	guanfacine	0,09	12	37	606	11	38
C02AC05	moxonidine	2,55	1	3	610	1	-2

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING	0,56	4	9	464	4	15
C02CA	Alpha-adrenoceptor blocking agents	0,56	4	9	464	4	15
C02CA01	prazosin	0,56	4	9	464	4	15
C02D	ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON	0,00	100	-	67	100	-
C02DD	Nitroferricyanide derivatives	0,00	100	-	67	100	-
C02DD01	nitroprusside	0,00	100	-	67	100	-
C02K	OTHER ANTIHYPERTENSIVES	0,06	2	6	7 056	2	-2
C02KX	Antihypertensives for pulmonary arterial hypertension	0,06	2	6	7 056	2	-2
C02KX01	bosentan	0,01	3	0	1 297	4	-1
C02KX02	ambrisentan	0,00	1	-7	343	2	-57
C02KX04	macitentan	0,03	1	9	3 586	1	5
C02KX05	riociguat	0,02	1	10	1 830	1	10
C03	DIURETICS	50,18	5	-1	9 223	20	1
C03A	LOW-CEILING DIURETICS, THIAZIDES	7,18	2	1	1 497	2	5
C03AA	Thiazides, plain	7,18	2	1	1 497	2	5
C03AA03	hydrochlorothiazide	7,18	2	1	1 497	2	5
C03B	LOW-CEILING DIURETICS, EXCL. THIAZIDES	0,49	5	0	306	21	30
C03BA	Sulfonamides, plain	0,49	5	0	306	21	30
C03BA08	metolazone	0,04	48	152	130	48	152
C03BA11	indapamide	0,46	1	-4	176	1	-4
C03C	HIGH-CEILING DIURETICS	34,63	7	-1	5 031	33	-4
C03CA	Sulfonamides, plain	34,63	7	-1	5 031	33	-4
C03CA01	furosemide	34,63	7	-1	5 031	33	-4
C03D	ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS	3,11	2	6	1 594	2	6
C03DA	Aldosterone antagonists	3,11	2	6	1 594	2	6
C03DA01	spironolactone	3,09	2	6	1 499	2	6
C03DA04	eplerenone	0,02	3	8	95	3	13
C03E	DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	4,76	1	-5	535	2	-12
C03EA	Low-ceiling diuretics and potassium-sparing agents	4,16	1	-5	426	1	-12

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C03EA01	hydrochlorothiazide and potassium-sparing agents	4,16	1	-5	426	1	-12
C03EB	High-ceiling diuretics and potassium-sparing agents	0,60	5	-11	109	5	-11
C03EB01	furosemide and potassium-sparing agents	0,60	5	-11	109	5	-11
C03X	OTHER DIURETICS	0,01	1	129	260	10	93
C03XA	Vasopressin antagonists	0,01	1	129	260	10	93
C03XA01	tolvaptan	0,01	1	129	260	10	93
C04	PERIPHERAL VASODILATORS	0,10	5	-10	69	5	-12
C04A	PERIPHERAL VASODILATORS	0,10	5	-10	69	5	-12
C04AD	Purine derivatives	0,10	5	-10	69	5	-12
C04AD03	pentoxifylline	0,10	5	-10	69	5	-12
C05	VASOPROTECTIVES	-	-	-	4 891	5	8
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	-	-	-	3 099	2	11
C05AA	Corticosteroids	-	-	-	2 971	2	12
C05AA01	hydrocortisone	-	-	-	58	36	-26
C05AA04	prednisolone	-	-	-	2 451	1	15
C05AA08	fluocortolone	-	-	-	462	1	6
C05AE	Muscle relaxants	-	-	-	128	3	-8
C05AE01	glyceryl trinitrate	-	-	-	128	3	-8
C05B	ANTIVARICOSE THERAPY	-	-	-	1 792	11	4
C05BA	Heparins or heparinoids for topical use	-	-	-	1 595	2	4
C05BA01	organo-heparinoid	-	-	-	1 595	2	4
C05BB	Sclerosing agents for local injection	-	-	-	197	87	3
C05BB02	polidocanol	-	-	-	197	87	3
C07	BETA BLOCKING AGENTS	63,93	2	-3	18 398	4	-5
C07A	BETA BLOCKING AGENTS	60,10	2	-2	16 603	4	-4
C07AA	Beta blocking agents, non-selective	2,68	2	0	1 501	2	4
C07AA05	propranolol	2,24	2	1	1 370	2	5
C07AA07	sotalol	0,44	2	-4	131	2	-4
C07AB	Beta blocking agents, selective	55,49	2	-2	14 206	3	-3
C07AB02	metoprolol	8,99	2	-7	3 560	4	-8



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C07AB03	atenolol	1,69	2	-11	335	2	-13
C07AB04	acebutolol	0,11	4	-1	58	4	-1
C07AB05	betaxolol	-	-	-100	0	-	-100
C07AB07	bisoprolol	42,25	2	0	9 681	2	0
C07AB08	celiprolol	0,64	1	-2	146	1	-2
C07AB09	esmolol	0,00	100	59	40	100	49
C07AB12	nebivolol	1,81	1	1	385	1	-17
C07AB14	landiolol	-	-	-	1	100	33
C07AG	Alpha and beta blocking agents	1,93	2	-5	896	36	-14
C07AG01	labetalol	0,07	7	41	442	71	-12
C07AG02	carvedilol	1,86	2	-6	454	2	-16
C07B	BETA BLOCKING AGENTS AND THIAZIDES	2,61	0	-15	873	0	-17
C07BB	Beta blocking agents, selective, and thiazides	2,61	0	-15	873	0	-17
C07BB02	metoprolol and thiazides	0,11	0	-65	50	0	-65
C07BB07	bisoprolol and thiazides	2,50	0	-9	784	0	-10
C07BB12	nebivolol and thiazides	-	-	-	38	0	0
C07F	BETA BLOCKING AGENTS, OTHER COMBINATIONS	1,21	1	-8	922	1	-9
C07FB	Beta blocking agent and calcium channel blockers	1,21	1	-8	922	1	-9
C07FB02	metoprolol and felodipine	1,21	1	-8	922	1	-9
C08	CALCIUM CHANNEL BLOCKERS	104,33	1	5	11 080	4	-3
C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	102,94	1	5	10 254	4	-2
C08CA	Dihydropyridine derivatives	102,94	1	5	10 254	4	-2
C08CA01	amlodipine	72,79	1	5	4 632	1	6
C08CA02	felodipine	7,92	1	5	1 878	1	-17
C08CA05	nifedipine	0,54	2	-21	407	2	-20
C08CA06	nimodipine	0,00	83	11	247	95	-19
C08CA10	nilvadipine	0,73	2	3	440	2	3
C08CA13	lercanidipine	20,96	1	6	2 650	1	0
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	1,38	2	-5	826	3	-7
C08DA	Phenylalkylamine derivatives	0,74	2	-1	244	2	0
C08DA01	verapamil	0,74	2	-1	244	2	0

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C08DB	Benzothiazepine derivatives	0,64	3	-10	582	3	-9
C08DB01	diltiazem	0,64	3	-10	582	3	-9
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	280,96	1	2	34 467	1	-11
C09A	ACE INHIBITORS, PLAIN	101,23	1	-3	5 212	1	-16
C09AA	ACE inhibitors, plain	101,23	1	-3	5 212	1	-16
C09AA02	enalapril	20,86	1	-5	1 829	1	-9
C09AA03	lisinopril	3,31	1	-5	310	2	-44
C09AA04	perindopril	4,45	1	-3	1 138	1	-28
C09AA05	ramipril	72,59	1	-2	1 930	1	-7
C09AA06	quinapril	0,01	0	-49	4	0	-49
C09B	ACE INHIBITORS, COMBINATIONS	10,79	0	-4	3 080	0	-12
C09BA	ACE inhibitors and diuretics	8,61	0	-5	1 976	0	-19
C09BA02	enalapril and diuretics	5,73	0	-5	870	0	-29
C09BA03	lisinopril and diuretics	1,04	1	-8	470	1	-11
C09BA04	perindopril and diuretics	0,93	1	-4	473	1	-6
C09BA05	ramipril and diuretics	0,89	0	-5	157	0	-5
C09BA06	quinapril and diuretics	0,02	0	-46	6	0	-46
C09BB	ACE inhibitors and calcium channel blockers	1,72	0	3	799	0	3
C09BB02	enalapril and lercanidipine	0,35	0	-1	121	0	-1
C09BB04	perindopril and amlodipine	1,36	0	3	678	0	4
C09BX	ACE inhibitors, other combinations	0,46	0	-3	305	0	-2
C09BX01	perindopril, amlodipine and indapamide	0,44	0	4	299	0	2
C09BX02	perindopril and bisoprolol	0,02	0	-63	6	0	-64
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN	134,63	1	7	11 377	1	-13
C09CA	Angiotensin II receptor blockers (ARBs), plain	134,63	1	7	11 377	1	-13
C09CA01	losartan	52,12	1	5	3 486	1	-36
C09CA02	eprosartan	0,11	2	-60	75	2	-63
C09CA03	valsartan	16,68	1	4	2 094	1	-2
C09CA06	candesartan	54,38	1	11	3 915	1	0
C09CA07	telmisartan	10,30	1	5	1 369	1	39
C09CA08	olmesartan medoxomil	1,04	0	-7	438	1	15
C09D	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS	34,32	0	1	14 798	1	-6

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C09DA	Angiotensin II receptor blockers (ARBs) and diuretics	29,03	0	0	8 170	0	-13
C09DA01	losartan and diuretics	12,44	0	0	2 970	0	-21
C09DA02	eprosartan and diuretics	0,30	0	-5	215	0	-10
C09DA03	valsartan and diuretics	4,50	0	-1	1 035	0	-6
C09DA06	candesartan and diuretics	7,62	0	1	2 981	0	-11
C09DA07	telmisartan and diuretics	3,84	0	-1	820	0	5
C09DA08	olmesartan medoxomil and diuretics	0,32	0	-7	149	0	-9
C09DB	Angiotensin II receptor blockers (ARBs) and calcium channel blockers	2,99	0	6	935	0	-32
C09DB01	valsartan and amlodipine	2,86	0	7	864	0	-33
C09DB02	olmesartan medoxomil and amlodipine	0,12	1	-11	71	1	-16
C09DX	Angiotensin II receptor blockers (ARBs), other combinations	2,30	1	9	5 693	2	15
C09DX01	valsartan, amlodipine and hydrochlorothiazide	1,77	0	5	1 056	0	-11
C09DX04	valsartan and sacubitril	0,53	2	24	4 637	2	23
C10	LIPID MODIFYING AGENTS	166,68	1	13	22 207	1	-6
C10A	LIPID MODIFYING AGENTS, PLAIN	166,53	1	13	21 825	1	-7
C10AA	HMG CoA reductase inhibitors	153,84	1	11	15 960	1	-17
C10AA01	simvastatin	31,30	1	-6	4 589	1	-31
C10AA02	lovastatin	0,09	1	-72	70	1	-69
C10AA03	pravastatin	1,78	2	-3	942	2	-8
C10AA04	fluvastatin	1,64	1	-7	730	1	22
C10AA05	atorvastatin	70,99	2	13	5 479	1	-11
C10AA07	rosuvastatin	48,05	1	26	4 150	1	-8
C10AB	Fibrates	0,52	1	0	413	1	-1
C10AB02	bezafibrate	0,08	1	11	98	1	11
C10AB04	gemfibrozil	-	-	-100	0	-	-100
C10AB05	fenofibrate	0,44	2	3	315	2	1
C10AC	Bile acid sequestrants	0,05	2	2 443	142	2	834
C10AC01	colestyramine	0,05	2	-	135	2	-
C10AC04	colesevelam	0,00	2	-56	7	2	-56
C10AX	Other lipid modifying agents	12,12	1	40	5 310	1	35
C10AX09	ezetimibe	11,96	1	40	1 388	1	-11

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C10AX13	evolocumab	0,11	1	72	3 078	1	72
C10AX14	alirocumab	0,05	0	41	823	0	44
C10AX16	inclisiran	-	-	-	22	41	-
C10B	LIPID MODIFYING AGENTS, COMBINATIONS	0,15	0	20	382	0	99
C10BA	Combinations of various lipid modifying agents	-	-	-	232	0	303
C10BA06	rosuvastatin and ezetimibe	-	-	-	232	0	303
C10BX	Lipid modifying agents in combination with other drugs	0,15	0	20	149	0	12
C10BX11	atorvastatin, amlodipine and perindopril	0,15	0	20	139	0	20
C10BX15	atorvastatin and perindopril	-	-	-	10	0	-42
<b>D</b>	<b>DERMATOLOGICALS</b>	<b>3,04</b>	<b>1</b>	<b>5</b>	<b>47 358</b>	<b>5</b>	<b>9</b>
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE	1,49	1	4	5 924	3	0
D01A	ANTIFUNGALS FOR TOPICAL USE	-	-	-	4 872	3	0
D01AA	Antibiotics	-	-	-	44	2	-7
D01AA02	natamycin	-	-	-	44	2	-7
D01AC	Imidazole and triazole derivatives	-	-	-	3 289	4	0
D01AC01	clotrimazole	-	-	-	215	1	-4
D01AC02	miconazole	-	-	-	999	7	1
D01AC07	tioconazole	-	-	-	40	0	-7
D01AC08	ketoconazole	-	-	-	1 169	1	1
D01AC10	bifonazole	-	-	-	29	0	-26
D01AC20	imidazoles/triazoles in combination with corticosteroids	-	-	-	837	6	0
D01AE	Other antifungals for topical use	-	-	-	1 539	1	0
D01AE14	ciclopirox	-	-	-	49	0	6
D01AE15	terbinafine	-	-	-	1 282	1	-2
D01AE16	amorolfine	-	-	-	208	1	11
D01B	ANTIFUNGALS FOR SYSTEMIC USE	1,49	1	4	1 052	1	0
D01BA	Antifungals for systemic use	1,49	1	4	1 052	1	0
D01BA02	terbinafine	1,49	1	4	1 052	1	0
D02	EMOLLIENTS AND PROTECTIVES	-	-	-	53	1	7
D02A	EMOLLIENTS AND PROTECTIVES	-	-	-	53	1	7
D02AE	Carbamide products	-	-	-	32	1	9
D02AE01	carbamide	-	-	-	32	1	9

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D02AX	Other emollients and protectives	-	-	-	21	0	4
D03	PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	-	-	-	7 130	2	5
D03A	CICATRIZANTS	-	-	-	7 130	2	5
D03AX	Other cicatrizants	-	-	-	7 130	2	5
D03AX03	dexpanthenol	-	-	-	7 130	2	5
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	-	-	-	644	0	70
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	-	-	-	644	0	70
D04AA	Antihistamines for topical use	-	-	-	644	0	70
D04AA04	tripelennamine	-	-	-	644	0	70
D05	ANTIPSORIATICS	0,16	1	-1	2 038	2	-8
D05A	ANTIPSORIATICS FOR TOPICAL USE	-	-	-	1 739	2	-9
D05AX	Other antipsoriatics for topical use	-	-	-	1 739	2	-9
D05AX02	calcipotriol	-	-	-	43	2	-1
D05AX03	calcitriol	-	-	-	26	1	-10
D05AX52	calcipotriol, combinations	-	-	-	1 670	2	-9
D05B	ANTIPSORIATICS FOR SYSTEMIC USE	0,16	1	-1	300	1	-2
D05BB	Retinoids for treatment of psoriasis	0,16	1	-1	300	1	-2
D05BB02	acitretin	0,16	1	-1	300	1	-2
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	-	-	-	4 742	3	0
D06A	ANTIBIOTICS FOR TOPICAL USE	-	-	-	2 317	5	4
D06AX	Other antibiotics for topical use	-	-	-	2 317	5	4
D06AX01	fusidic acid	-	-	-	997	9	-2
D06AX04	neomycin	-	-	-	1 297	2	10
D06AX09	mupirocin	-	-	-	23	18	-11
D06B	CHEMOTHERAPEUTICS FOR TOPICAL USE	-	-	-	2 425	1	-3
D06BB	Antivirals	-	-	-	2 099	1	-2
D06BB03	aciclovir	-	-	-	1 136	1	1
D06BB06	penciclovir	-	-	-	190	0	-2
D06BB10	imiquimod	-	-	-	590	1	-7
D06BB53	aciclovir, combinations	-	-	-	183	0	-7

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D06BX	Other chemotherapeutics	-	-	-	326	0	-6
D06BX01	metronidazole	-	-	-	326	0	-5
D06BX02	ingenol mebutate	-	-	-	0	-	-100
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	-	-	-	12 613	3	2
D07A	CORTICOSTEROIDS, PLAIN	-	-	-	8 977	4	3
D07AA	Corticosteroids, weak (group I)	-	-	-	3 998	2	7
D07AA02	hydrocortisone	-	-	-	3 998	2	7
D07AB	Corticosteroids, moderately potent (group II)	-	-	-	1 510	3	0
D07AB01	clobetasone	-	-	-	1	0	-85
D07AB02	hydrocortisone butyrate	-	-	-	872	2	-6
D07AB08	desonide	-	-	-	636	4	12
D07AC	Corticosteroids, potent (group III)	-	-	-	2 663	7	0
D07AC01	betamethasone	-	-	-	1 880	9	10
D07AC03	desoximetasone	-	-	-	0	-	-100
D07AC13	mometasone	-	-	-	751	3	-16
D07AC14	methylprednisolone aceponate	-	-	-	32	0	-11
D07AD	Corticosteroids, very potent (group IV)	-	-	-	807	3	4
D07AD01	clobetasol	-	-	-	807	3	4
D07B	CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS	-	-	-	1 240	3	-1
D07BA	Corticosteroids, weak, combinations with antiseptics	-	-	-	716	2	-2
D07BA04	hydrocortisone and antiseptics	-	-	-	716	2	-2
D07BB	Corticosteroids, moderately potent, combinations with antiseptics	-	-	-	350	3	0
D07BB04	hydrocortisone butyrate and antiseptics	-	-	-	350	3	0
D07BC	Corticosteroids, potent, combinations with antiseptics	-	-	-	174	6	2
D07BC01	betamethasone and antiseptics	-	-	-	174	6	2
D07C	CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS	-	-	-	1 609	4	1
D07CA	Corticosteroids, weak, combinations with antibiotics	-	-	-	933	4	1

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D07CA01	hydrocortisone and antibiotics	-	-	-	933	4	1
D07CC	Corticosteroids, potent, combinations with antibiotics	-	-	-	676	4	1
D07CC01	betamethasone and antibiotics	-	-	-	676	4	1
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS	-	-	-	787	2	-1
D07XA	Corticosteroids, weak, other combinations	-	-	-	274	0	1
D07XA01	hydrocortisone	-	-	-	274	0	1
D07XC	Corticosteroids, potent, other combinations	-	-	-	513	3	-2
D07XC01	betamethasone, combinations	-	-	-	513	3	-2
D08	ANTISEPTICS AND DISINFECTANTS	-	-	-	1 097	73	6
D08A	ANTISEPTICS AND DISINFECTANTS	-	-	-	1 097	73	6
D08AC	Biguanides and amidines	-	-	-	721	99	13
D08AC02	chlorhexidine	-	-	-	41	89	-3
D08AC52	chlorhexidine, combinations	-	-	-	680	100	15
D08AG	Iodine products	-	-	-	376	21	-7
D08AG02	povidone-iodine	-	-	-	376	21	-7
D09	MEDICATED DRESSINGS	-	-	-	134	21	1
D09A	MEDICATED DRESSINGS	-	-	-	134	21	1
D09AB	Zinc bandages	-	-	-	134	21	1
D09AB01	zinc bandage without supplements	-	-	-	134	21	1
D10	ANTI-ACNE PREPARATIONS	1,24	1	4	3 747	1	2
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE	-	-	-	2 378	1	3
D10AD	Retinoids for topical use in acne	-	-	-	919	2	4
D10AD01	tretinoin	-	-	-	223	1	-5
D10AD03	adapalene	-	-	-	155	1	-7
D10AD53	adapalene, combinations	-	-	-	542	3	13
D10AE	Peroxides	-	-	-	461	0	0
D10AE01	benzoyl peroxide	-	-	-	461	0	0
D10AF	Antiinfectives for treatment of acne	-	-	-	805	1	2
D10AF01	clindamycin	-	-	-	216	1	-2
D10AF51	clindamycin, combinations	-	-	-	589	1	3
D10AX	Other anti-acne preparations for topical use	-	-	-	193	0	6
D10AX03	azelaic acid	-	-	-	193	0	6

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D10B	ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE	1,24	1	4	1 368	1	1
D10BA	Retinoids for treatment of acne	1,24	1	4	1 368	1	1
D10BA01	isotretinoin	1,24	1	4	1 368	1	1
D11	OTHER DERMATOLOGICAL PREPARATIONS	0,15	4	43	9 237	6	55
D11A	OTHER DERMATOLOGICAL PREPARATIONS	0,15	4	43	9 237	6	55
D11AC	Medicated shampoos	-	-	-	107	0	-5
D11AC03	selenium compounds	-	-	-	107	0	-5
D11AH	Agents for dermatitis, excluding corticosteroids	0,09	7	85	7 492	8	73
D11AH01	tacrolimus	-	-	-	984	2	-2
D11AH02	pimecrolimus	-	-	-	447	1	2
D11AH04	alitretinoin	0,02	0	12	187	0	-45
D11AH05	dupilumab	0,07	10	128	5 874	10	131
D11AX	Other dermatologicals	0,06	0	8	1 637	0	7
D11AX01	minoxidil	-	-	-	971	0	10
D11AX10	finasteride	0,06	0	8	217	0	6
D11AX16	eflornithine	-	-	-	39	0	-12
D11AX18	diclofenac	-	-	-	3	8	-30
D11AX21	brimonidine	-	-	-	97	1	2
D11AX22	ivermectin	-	-	-	305	0	3
D11AX24	deoxycholic acid	-	-	-	5	0	200
<b>G</b>	<b>GENITO URINARY SYSTEM AND SEX HORMONES</b>	<b>139,31</b>	<b>8</b>	<b>-16</b>	<b>91 994</b>	<b>7</b>	<b>-12</b>
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	0,75	1	0	3 163	1	-2
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS	0,75	1	0	3 163	1	-2
G01AA	Antibiotics	0,06	0	-2	391	0	-8
G01AA10	clindamycin	0,06	0	-2	391	0	-8
G01AC	Quinoline derivatives	0,02	0	7	229	0	0
G01AC05	dequalinium	0,02	0	7	229	0	0
G01AF	Imidazole derivatives	0,67	1	0	2 544	1	-1
G01AF01	metronidazole	0,15	1	-3	723	1	-6
G01AF02	clotrimazole	0,43	1	4	1 717	1	2



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G01AF04	miconazole	0,08	2	-13	104	2	-16
G02	OTHER GYNECOLOGICALS	2,18	12	-8	7 594	39	-1
G02A	UTEROTONICS	0,00	100	-3	121	100	68
G02AD	Prostaglandins	0,00	100	-3	121	100	68
G02AD02	dinoprostone	0,00	100	-18	10	100	-18
G02AD06	misoprostol	0,00	100	86	111	100	86
G02B	CONTRACEPTIVES FOR TOPICAL USE	2,16	12	-8	7 136	36	-1
G02BA	Intrauterine contraceptives	-	-	-	6 000	42	1
G02BA03	plastic IUD with progestogens	-	-	-	6 000	42	1
G02BB	Intravaginal contraceptives	2,16	12	-8	1 137	5	-11
G02BB01	vaginal ring with progestogen and estrogen	2,16	12	-8	1 137	5	-11
G02C	OTHER GYNECOLOGICALS	0,02	12	-19	336	85	-23
G02CB	Prolactine inhibitors	0,02	11	-19	55	10	-8
G02CB01	bromocriptine	0,02	11	-26	15	11	-26
G02CB03	cabergoline	0,01	10	1	40	10	1
G02CX	Other gynecologicals	0,00	99	-15	282	99	-25
G02CX01	atosiban	0,00	99	-15	282	99	-25
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	81,18	12	-25	50 333	6	-11
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	43,25	22	1	17 872	15	1
G03AA	Progestogens and estrogens, fixed combinations	24,17	21	1	9 222	14	-4
G03AA07	levonorgestrel and ethinylestradiol	0,94	24	8	233	17	3
G03AA09	desogestrel and ethinylestradiol	2,75	18	-8	694	5	-11
G03AA10	gestodene and ethinylestradiol	4,11	16	-11	1 023	5	-13
G03AA11	norgestimate and ethinylestradiol	-	-	-100	0	-	-100
G03AA12	drospirenone and ethinylestradiol	11,45	21	1	5 264	16	-9
G03AA13	norelgestromin and ethinylestradiol	0,40	12	-6	238	12	-6
G03AA14	nomegestrol and estradiol	1,62	13	25	960	13	25
G03AA16	dienogest and ethinylestradiol	2,90	31	23	810	14	21
G03AB	Progestogens and estrogens, sequential preparations	1,39	7	-12	881	7	-11
G03AB08	dienogest and estradiol	1,39	7	-12	881	7	-11
G03AC	Progestogens	17,64	26	3	6 900	21	12

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G03AC01	norethisterone	0,26	4	-32	60	4	-64
G03AC03	levonorgestrel	0,41	6	0	247	15	-8
G03AC08	etonogestrel	4,91	58	9	1 059	58	8
G03AC09	desogestrel	12,07	14	1	3 586	12	-13
G03AC10	drospirenone	-	-	-	1 949	18	197
G03AD	Emergency contraceptives	0,04	2	18	869	2	-9
G03AD01	levonorgestrel	0,02	3	45	428	2	-8
G03AD02	ulipristal	0,02	1	-8	441	2	-11
G03B	ANDROGENS	2,50	0	112	5 971	0	1
G03BA	3-oxoandrogen (4) derivatives	2,50	0	112	5 971	0	1
G03BA03	testosterone	2,50	0	112	5 971	0	1
G03C	ESTROGENS	21,13	1	-58	14 885	1	-33
G03CA	Natural and semisynthetic estrogens, plain	20,59	1	-58	14 704	1	-33
G03CA03	estradiol	15,45	0	-67	12 042	0	-37
G03CA04	estriol	5,14	2	126	2 662	1	-10
G03CC	Estrogens, combinations with other drugs	-	-	-	0	-	-100
G03CC07	conjugated estrogens and bazedoxifene	-	-	-	0	-	-100
G03CX	Other estrogens	0,54	1	-13	180	1	-12
G03CX01	tibolone	0,54	1	-13	180	1	-12
G03D	PROGESTOGENS	2,38	1	7	1 504	0	1
G03DA	Pregnen (4) derivatives	0,59	1	10	449	1	5
G03DA02	medroxyprogesterone	0,34	1	-8	64	1	-8
G03DA04	progesterone	0,24	1	49	385	1	8
G03DB	Pregnadien derivatives	0,72	0	1	611	0	-1
G03DB01	dydrogesterone	0,57	0	-2	311	0	-2
G03DB08	dienogest	0,15	0	16	300	0	0
G03DC	Estren derivatives	1,08	1	10	443	1	0
G03DC02	norethisterone	0,88	0	-10	397	1	-11
G03DC03	lynestrenol	0,20	1	-	46	1	-
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION	9,53	0	-3	4 192	0	7
G03FA	Progestogens and estrogens, combinations	7,68	0	6	3 458	0	6
G03FA01	norethisterone and estrogen	3,03	0	33	1 422	0	31
G03FA12	medroxyprogesterone and estrogen	1,12	0	-3	500	0	-3

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G03FA14	dydrogesterone and estrogen	3,22	0	-8	1 297	0	-8
G03FA17	drospirenone and estrogen	0,32	0	-3	238	0	-3
G03FB	Progestogens and estrogens, sequential preparations	1,85	0	-29	735	0	7
G03FB05	norethisterone and estrogen	0,58	0	-54	266	0	44
G03FB06	medroxyprogesterone and estrogen	0,08	0	-20	16	0	-25
G03FB08	dydrogesterone and estrogen	1,19	0	-6	452	0	-6
G03G	GONADOTROPHINS AND OTHER OVULATION STIMULANTS	0,28	1	17	4 832	1	12
G03GA	Gonadotrophins	0,28	1	17	4 832	1	12
G03GA01	chorionic gonadotrophin	0,18	0	14	125	0	14
G03GA02	human menopausal gonadotrophin	0,05	0	33	1 667	0	26
G03GA04	urofollitropin	0,00	0	-37	24	0	-37
G03GA05	follitropin alfa	0,05	2	17	1 962	2	10
G03GA06	follitropin beta	-	-	-100	0	-	-100
G03GA07	lutropin alfa	-	-	-100	0	-	-100
G03GA08	choriogonadotropin alfa	0,00	0	9	206	0	8
G03GA09	corifollitropin alfa	0,00	0	10	176	0	-1
G03GA30	combinations	-	-	-	672	0	2
G03H	ANTIANDROGENS	1,95	3	-24	592	1	-37
G03HA	Antiandrogens, plain preparations	0,04	6	-9	90	6	-13
G03HA01	cyproterone	0,04	6	-9	90	6	-13
G03HB	Antiandrogens and estrogens	1,92	3	-24	503	1	-40
G03HB01	cyproterone and estrogen	1,92	3	-24	503	1	-40
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0,15	4	150	485	64	84
G03XB	Progesterone receptor modulators	0,01	87	2	323	97	59
G03XB01	mifepristone	0,01	99	6	316	99	63
G03XB02	ulipristal	0,00	0	-20	7	0	-20
G03XX	Other sex hormones and modulators of the genital system	0,14	0	167	162	0	167
G03XX01	prasterone	0,14	0	167	162	0	167
G04	UROLOGICALS	55,19	2	3	30 905	2	-16
G04B	UROLOGICALS	20,04	2	2	18 728	2	-5

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G04BD	Drugs for urinary frequency and incontinence	7,66	2	5	12 478	3	4
G04BD04	oxybutynin	0,09	2	-35	134	2	-34
G04BD07	tolterodine	0,21	3	-12	229	3	-21
G04BD08	solifenacin	1,37	2	2	548	2	-18
G04BD09	tropium	0,18	1	-2	189	1	-2
G04BD10	darifenacin	0,03	2	2	39	2	2
G04BD11	fesoterodine	0,41	2	-7	559	2	-9
G04BD12	mirabegron	5,38	2	9	10 781	3	8
G04BE	Drugs used in erectile dysfunction	9,16	0	2	5 184	1	-22
G04BE01	alprostadil	0,03	0	-92	560	0	34
G04BE03	sildenafil	7,73	0	1	2 238	2	-2
G04BE08	tadalafil	1,38	0	39	2 153	0	-41
G04BE09	vardenafil	0,01	0	2	66	0	-13
G04BE10	avanafil	0,01	0	-9	51	0	-9
G04BE30	combinations	0,00	1	-26	115	1	-26
G04BX	Other urologicals	3,22	4	-2	1 066	4	-2
G04BX01	magnesium hydroxide	3,21	4	-2	1 023	4	-2
G04BX14	dapoxetine	0,01	0	-10	43	0	-9
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	35,15	2	3	12 177	2	-28
G04CA	Alpha-adrenoreceptor antagonists	26,05	2	5	7 141	2	-36
G04CA01	alfuzosin	6,27	1	3	1 371	1	-28
G04CA02	tamsulosin	12,70	2	5	3 473	2	0
G04CA52	tamsulosin and dutasteride	7,05	1	6	2 229	2	-61
G04CA53	tamsulosin and solifenacin	0,03	0	7	68	0	6
G04CB	Testosterone-5-alpha reductase inhibitors	8,60	2	-3	4 674	2	-11
G04CB01	finasteride	5,71	2	-6	4 256	2	-11
G04CB02	dutasteride	2,89	2	4	419	2	-6
G04CX	Other drugs used in benign prostatic hypertrophy	0,51	0	-10	361	0	-14
G04CX02	sabalıs serrulatae fructus	0,51	0	-10	361	0	-14
<b>H</b>	<b>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</b>	<b>55,43</b>	<b>6</b>	<b>-4</b>	<b>46 077</b>	<b>19</b>	<b>-7</b>
H01	PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES	1,46	2	-55	25 362	10	-13

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
H01A	ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES	0,33	0	5	9 906	10	-1
H01AB	Thyrotrophin	0,00	100	-10	994	100	-10
H01AB01	thyrotrophin alfa	0,00	100	-10	994	100	-10
H01AC	Somatropin and somatropin agonists	0,33	0	5	8 395	0	1
H01AC01	somatropin	0,33	0	5	8 395	0	1
H01AX	Other anterior pituitary hormones and analogues	0,00	1	8	518	1	-2
H01AX01	pegvisomant	0,00	1	8	518	1	-2
H01B	POSTERIOR PITUITARY LOBE HORMONES	0,80	3	-69	2 717	36	4
H01BA	Vasopressin and analogues	0,79	1	-70	2 462	30	3
H01BA01	vasopressin (argipressin)	0,00	100	-8	128	100	-6
H01BA02	desmopressin	0,78	1	-70	1 813	5	-3
H01BA04	terlipressin	0,00	100	33	521	100	33
H01BB	Oxytocin and analogues	0,02	100	-24	255	100	22
H01BB02	oxytocin	0,01	100	-32	55	100	-44
H01BB03	carbetocin	0,00	100	82	201	100	82
H01C	HYPOTHALAMIC HORMONES	0,32	2	6	12 738	4	-24
H01CA	Gonadotrophin-releasing hormones	0,05	0	26	298	0	22
H01CA02	nafarelin	0,05	0	26	298	0	22
H01CB	Somatostatin and analogues	0,26	3	2	12 102	5	-25
H01CB02	octreotide	0,12	5	0	3 873	13	-48
H01CB03	lanreotide	0,14	1	4	8 176	1	-6
H01CB05	pasireotide	0,00	30	130	53	32	112
H01CC	Anti gonadotropin releasing hormones	0,01	2	17	338	2	16
H01CC01	ganirelix	0,01	2	18	329	2	18
H01CC02	cetrorelix	0,00	0	-35	9	0	-35
H01CC54	relugolix, estradiol and norethisterone	-	-	-	0	0	-
H02	CORTICOSTEROIDS FOR SYSTEMIC USE	17,41	16	-4	11 056	52	6
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	17,32	16	-4	8 877	50	6
H02AA	Mineralocorticoids	0,57	6	-13	129	6	-13
H02AA02	fludrocortisone	0,57	6	-13	129	6	-13
H02AB	Glucocorticoids	16,74	16	-4	8 748	51	6
H02AB01	betamethasone	0,47	84	78	230	87	-3

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
H02AB02	dexamethasone	2,40	41	2	2 912	57	19
H02AB04	methylprednisolone	1,03	37	-28	1 725	69	-1
H02AB06	prednisolone	11,04	6	-4	1 453	13	8
H02AB07	prednisone	0,50	5	-10	95	5	12
H02AB08	triamcinolone	0,09	70	-4	845	71	-6
H02AB09	hydrocortisone	1,21	16	3	1 488	40	0
H02B	CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS	0,09	62	5	2 179	62	5
H02BX	Corticosteroids for systemic use, combinations	0,09	62	5	2 179	62	5
H02BX01	methylprednisolone, combinations	0,09	62	5	2 179	62	5
H03	THYROID THERAPY	36,31	1	0	6 938	2	-1
H03A	THYROID PREPARATIONS	35,80	1	0	6 322	2	0
H03AA	Thyroid hormones	35,80	1	0	6 322	2	0
H03AA01	levothyroxine sodium	35,80	1	0	6 322	2	0
H03B	ANTITHYROID PREPARATIONS	0,51	4	-6	616	4	-6
H03BB	Sulphur-containing imidazole derivatives	0,51	4	-6	616	4	-6
H03BB01	carbimazole	0,51	4	-6	616	4	-6
H04	PANCREATIC HORMONES	0,01	57	17	302	47	34
H04A	GLYCOGENOLYTIC HORMONES	0,01	57	17	302	47	34
H04AA	Glycogenolytic hormones	0,01	57	17	302	47	34
H04AA01	glucagon	0,01	57	17	302	47	34
H05	CALCIUM HOMEOSTASIS	0,25	10	1	2 419	13	-14
H05A	PARATHYROID HORMONES AND ANALOGUES	0,05	11	-10	721	11	-12
H05AA	Parathyroid hormones and analogues	0,05	11	-10	721	11	-12
H05AA02	teriparatide	0,05	11	-10	721	11	-12
H05B	ANTI-PARATHYROID AGENTS	0,20	9	4	1 698	14	-14
H05BA	Calcitonin preparations	0,00	97	35	38	97	35
H05BA01	calcitonin (salmon synthetic)	0,00	97	35	38	97	35
H05BX	Other anti-parathyroid agents	0,20	9	4	1 660	12	-15
H05BX01	cinacalcet	0,18	6	7	1 502	6	-16
H05BX02	paricalcitol	0,01	49	-21	124	62	-20
H05BX04	etelcalcetide	0,00	100	89	34	100	89
<b>J</b>	<b>ANTIINFECTIVES FOR SYSTEMIC USE</b>	<b>13,39</b>	<b>22</b>	<b>-13</b>	<b>245 118</b>	<b>77</b>	<b>-5</b>
J01	ANTIBACTERIALS FOR SYSTEMIC USE	11,32	17	-15	38 998	56	-6

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J01A	TETRACYCLINES	2,35	6	-7	1 592	20	-9
J01AA	Tetracyclines	2,35	6	-7	1 592	20	-9
J01AA02	doxycycline	1,21	11	-10	665	10	-9
J01AA04	lymecycline	0,84	1	3	482	1	3
J01AA07	tetracycline	0,29	3	-19	204	3	10
J01AA12	tigecycline	0,00	100	-33	241	100	-33
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS	3,52	15	-4	16 352	60	-2
J01CA	Penicillins with extended spectrum	1,77	9	-3	4 936	27	0
J01CA01	ampicillin	0,01	100	-51	1 010	100	16
J01CA04	amoxicillin	1,19	10	-1	2 690	9	3
J01CA08	pivmecillinam	0,58	8	-5	1 236	7	-15
J01CE	Beta-lactamase sensitive penicillins	0,90	11	-11	1 673	40	7
J01CE01	benzylpenicillin	0,05	94	-1	647	95	-11
J01CE02	phenoxymethylpenicillin	0,85	6	-12	1 026	6	22
J01CF	Beta-lactamase resistant penicillins	0,24	50	27	1 282	58	29
J01CF02	cloxacillin	0,12	91	38	744	91	39
J01CF05	flucloxacillin	0,12	11	18	538	11	17
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	0,61	25	-2	8 462	84	-8
J01CR02	amoxicillin and beta-lactamase inhibitor	0,52	12	-2	1 453	10	13
J01CR05	piperacillin and beta-lactamase inhibitor	0,09	99	-3	7 008	100	-12
J01D	OTHER BETA-LACTAM ANTIBACTERIALS	2,19	35	-41	10 326	62	-8
J01DB	First-generation cephalosporins	1,52	8	-3	4 058	8	-7
J01DB01	cefalexin	1,51	8	-3	4 037	8	-8
J01DB04	cefazolin	0,00	99	36	21	98	56
J01DC	Second-generation cephalosporins	0,56	97	-72	2 830	98	-10
J01DC02	cefuroxime	0,56	97	-72	2 830	98	-10
J01DD	Third-generation cephalosporins	0,07	97	-21	1 350	93	-3
J01DD01	cefotaxime	0,00	100	-59	2	100	-20
J01DD02	ceftazidime	0,00	100	-18	63	100	-7
J01DD04	ceftriaxone	0,06	97	-22	1 009	93	-10
J01DD52	ceftazidime and beta-lactamase inhibitor	0,00	93	38	276	93	38
J01DE	Fourth-generation cephalosporins	0,00	100	442	32	100	444
J01DE01	cefepime	0,00	100	442	32	100	444

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J01DF	Monobactams	0,00	100	53	49	100	53
J01DF01	aztreonam	0,00	100	53	49	100	53
J01DH	Carbapenems	0,04	100	-3	1 922	99	0
J01DH02	meropenem	0,03	100	-4	816	100	-10
J01DH03	ertapenem	0,01	100	0	1 007	100	0
J01DH51	imipenem and cilastatin	0,00	100	-	38	100	-
J01DH52	meropenem and vaborbactam	-	-	-	3	100	-
J01DH56	imipenem, cilastatin and relebactam	-	-	-	58	86	-
J01DI	Other cephalosporins and penems	0,00	100	-50	85	100	-71
J01DI02	ceftaroline fosamil	0,00	100	-7	119	100	-7
J01DI54	ceftolozane and beta-lactamase inhibitor	0,00	100	-120	-34	100	-120
J01E	SULFONAMIDES AND TRIMETHOPRIM	1,02	9	2	1 384	8	1
J01EA	Trimethoprim and derivatives	0,68	8	-3	808	7	-1
J01EA01	trimethoprim	0,68	8	-3	808	7	-1
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives	0,34	11	13	576	10	5
J01EE01	sulfamethoxazole and trimethoprim	0,17	12	44	231	12	11
J01EE02	sulfadiazine and trimethoprim	0,17	10	-7	345	9	1
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	0,49	22	-12	2 263	52	-9
J01FA	Macrolides	0,26	22	-17	1 029	48	-7
J01FA01	erythromycin	0,00	100	3	96	100	2
J01FA06	roxithromycin	0,03	12	-23	70	12	-30
J01FA09	clarithromycin	0,04	24	-26	176	33	-18
J01FA10	azithromycin	0,19	22	-14	688	49	-1
J01FF	Lincosamides	0,23	22	-6	1 234	55	-11
J01FF01	clindamycin	0,23	22	-6	1 234	55	-11
J01G	AMINOGLYCOSIDE ANTIBACTERIALS	0,01	50	-13	840	47	-22
J01GB	Other aminoglycosides	0,01	50	-13	840	47	-22
J01GB01	tobramycin	0,01	38	-14	595	26	-18
J01GB03	gentamicin	0,00	95	17	120	93	1
J01GB06	amikacin	0,00	100	-40	125	100	-46
J01M	QUINOLONE ANTIBACTERIALS	0,49	26	-11	1 815	42	-26
J01MA	Fluoroquinolones	0,49	26	-11	1 815	42	-26



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J01MA02	ciprofloxacin	0,32	18	-2	1 088	30	-12
J01MA12	levofloxacin	0,14	39	-22	547	53	-32
J01MA14	moxifloxacin	0,03	43	-32	180	81	-55
J01X	OTHER ANTIBACTERIALS	1,26	10	-6	4 426	63	-3
J01XA	Glycopeptide antibacterials	0,03	97	10	1 031	97	-2
J01XA01	vancomycin	0,03	97	12	768	96	3
J01XA02	teicoplanin	0,00	100	-78	42	100	-78
J01XA04	dalbavancin	0,00	100	92	220	100	92
J01XB	Polymyxins	0,00	3	-17	147	3	-17
J01XB01	colistin	0,00	3	-17	147	3	-17
J01XC	Steroid antibacterials	-	-	-100	0	-	-100
J01XC01	fusidic acid	-	-	-100	0	-	-100
J01XD	Imidazole derivatives	0,05	100	-9	921	100	-11
J01XD01	metronidazole	0,05	100	-9	921	100	-11
J01XE	Nitrofurantoin derivatives	0,32	4	1	558	3	0
J01XE01	nitrofurantoin	0,32	4	1	558	3	0
J01XX	Other antibacterials	0,87	4	-9	1 769	49	2
J01XX01	fosfomicin	0,00	98	-4	9	98	-4
J01XX05	methenamine	0,86	3	-9	849	3	1
J01XX08	linezolid	0,01	60	-7	359	79	-17
J01XX09	daptomycin	0,00	100	33	552	100	23
J02	ANTIMYCOTICS FOR SYSTEMIC USE	0,35	15	-1	12 518	75	-5
J02A	ANTIMYCOTICS FOR SYSTEMIC USE	0,35	15	-1	12 518	75	-5
J02AA	Antibiotics	0,01	100	11	1 925	100	8
J02AA01	amphotericin	0,01	100	11	1 925	100	8
J02AB	Imidazole derivatives	0,00	100	-93	1	100	-93
J02AB02	ketoconazole	0,00	100	-93	1	100	-93
J02AC	Triazole and tetrazole derivatives	0,33	11	-1	3 826	20	-7
J02AC01	fluconazole	0,23	12	-4	1 885	12	-9
J02AC02	itraconazole	0,08	2	2	388	2	1
J02AC03	voriconazole	0,01	21	23	239	41	-3
J02AC04	posaconazole	0,01	33	8	534	44	-26
J02AC05	isavuconazole	0,00	19	31	779	24	14
J02AX	Other antimycotics for systemic use	0,01	100	-3	6 766	100	-8

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J02AX04	caspofungin	0,00	100	-12	1 108	100	-40
J02AX05	micafungin	0,00	100	-4	2 521	100	-3
J02AX06	anidulafungin	0,00	100	9	3 137	100	9
J04	ANTIMYCOBACTERIALS	0,13	86	-16	739	89	-4
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS	0,13	86	-16	739	89	-4
J04AA	Aminosalicylic acid and derivatives	-	-	-100	0	-	-100
J04AA01	aminosalicylic acid	-	-	-100	0	-	-100
J04AB	Antibiotics	0,07	74	-11	358	78	-3
J04AB02	rifampicin	0,06	71	-16	257	71	-16
J04AB04	rifabutin	0,01	98	57	101	98	57
J04AC	Hydrazides	0,03	97	-27	86	97	-22
J04AC01	isoniazid	0,03	97	-27	86	97	-22
J04AK	Other drugs for treatment of tuberculosis	0,03	100	-12	296	100	4
J04AK01	pyrazinamide	0,01	99	-33	62	99	-27
J04AK02	ethambutol	0,02	100	1	165	100	7
J04AK05	bedaquiline	0,00	100	50	70	100	50
J05	ANTIVIRALS FOR SYSTEMIC USE	1,59	54	3	127 779	93	0
J05A	DIRECT ACTING ANTIVIRALS	1,59	54	3	127 779	93	0
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	0,76	7	6	10 700	36	2
J05AB01	aciclovir	0,33	3	5	2 605	22	-9
J05AB06	ganciclovir	0,00	100	-18	143	100	-18
J05AB09	famciclovir	0,01	9	-12	118	9	-12
J05AB11	valaciclovir	0,39	3	9	4 786	3	6
J05AB14	valganciclovir	0,03	100	-2	3 048	100	9
J05AE	Protease inhibitors	0,03	100	-18	298	100	-40
J05AE03	ritonavir	0,00	100	-16	88	100	-15
J05AE08	atazanavir	0,01	100	-33	69	100	-52
J05AE10	darunavir	0,02	100	-13	141	100	-44
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors	0,08	99	8	1 219	100	7
J05AF01	zidovudine	0,00	100	-	2	100	-
J05AF05	lamivudine	0,00	100	-24	38	100	-23
J05AF06	abacavir	0,00	100	-14	39	100	-14

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J05AF07	tenofovir disoproxil	0,06	100	11	769	100	17
J05AF08	adefovir dipivoxil	0,00	100	-3	30	100	-3
J05AF09	emtricitabine	0,00	100	0	8	100	0
J05AF10	entecavir	0,01	96	20	106	97	-9
J05AF13	tenofovir alafenamide	0,01	100	3	226	100	-4
J05AG	Non-nucleoside reverse transcriptase inhibitors	0,05	100	17	959	100	26
J05AG01	nevirapine	0,02	100	-2	180	100	-13
J05AG03	efavirenz	0,01	100	-5	111	100	-4
J05AG04	etravirine	0,00	100	-36	53	100	-36
J05AG05	rilpivirine	0,01	100	68	210	100	57
J05AG06	doravirine	0,01	100	81	405	100	81
J05AH	Neuraminidase inhibitors	0,00	35	-96	16	42	-96
J05AH02	oseltamivir	0,00	35	-96	16	42	-96
J05AJ	Integrase inhibitors	0,20	100	7	7 516	100	7
J05AJ01	raltegravir	0,07	100	-2	2 094	100	-4
J05AJ03	dolutegravir	0,13	100	9	5 295	100	9
J05AJ04	cabotegravir	0,00	100	-	127	100	-
J05AP	Antivirals for treatment of HCV infections	0,07	100	-1	82 773	100	-2
J05AP01	ribavirin	0,00	100	-71	6	100	-86
J05AP08	sofosbuvir	-	-	-100	0	-	-100
J05AP51	sofosbuvir and ledipasvir	0,00	100	-59	148	100	-59
J05AP54	elbasvir and grazoprevir	0,00	100	-32	2 023	100	-54
J05AP55	sofosbuvir and velpatasvir	0,04	100	-14	50 135	100	-14
J05AP56	sofosbuvir, velpatasvir and voxilaprevir	0,00	100	31	1 582	100	31
J05AP57	glecaprevir and pibrentasvir	0,03	100	44	28 879	100	44
J05AR	Antivirals for treatment of HIV infections, combinations	0,39	94	3	22 149	100	2
J05AR01	zidovudine and lamivudine	-	-	-100	0	-	-100
J05AR02	lamivudine and abacavir	0,03	100	-2	131	100	-16
J05AR03	tenofovir disoproxil and emtricitabine	0,18	86	38	1 499	95	23
J05AR06	emtricitabine, tenofovir disoproxil and efavirenz	0,01	100	-9	123	100	-36
J05AR08	emtricitabine, tenofovir disoproxil and rilpivirine	0,00	93	-13	112	93	-18
J05AR09	emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat	0,00	100	-42	60	100	-38

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J05AR10	lopinavir and ritonavir	0,00	100	-89	3	100	-88
J05AR13	lamivudine, abacavir and dolutegravir	0,07	100	-15	5 220	100	-15
J05AR14	darunavir and cobicistat	0,00	100	-37	153	100	-37
J05AR17	emtricitabine and tenofovir alafenamide	0,06	100	-13	2 331	100	-12
J05AR18	emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat	0,01	100	-23	859	100	-21
J05AR19	emtricitabine, tenofovir alafenamide and rilpivirine	0,02	100	-24	1 057	100	-26
J05AR20	emtricitabine, tenofovir alafenamide and bictegravir	-	-	-	4 889	100	6
J05AR21	dolutegravir and rilpivirine	-	-	-	195	100	-9
J05AR22	emtricitabine, tenofovir alafenamide, darunavir and cobicistat	0,02	100	-7	892	100	-12
J05AR24	lamivudine, tenofovir disoproxil and doravirine	-	-	-	3 013	100	58
J05AR25	lamivudine and dolutegravir	-	-	-	1 612	100	194
J05AX	Other antivirals	0,00	46	57	2 150	32	71
J05AX09	maraviroc	0,00	100	6	87	100	6
J05AX18	letermovir	0,00	29	83	2 062	29	76
J05AX25	baloxavir marboxil	0,00	0	-	1	0	-
J06	IMMUNE SERA AND IMMUNOGLOBULINS	-	-	-	49 824	73	-4
J06B	IMMUNOGLOBULINS	-	-	-	49 824	73	-4
J06BA	Immunoglobulins, normal human	-	-	-	48 283	72	-5
J06BA01	immunoglobulins, normal human, for extravascular adm.	-	-	-	13 884	3	31
J06BA02	immunoglobulins, normal human, for intravascular adm.	-	-	-	34 399	100	-14
J06BB	Specific immunoglobulins	-	-	-	691	100	7
J06BB01	anti-D (rh) immunoglobulin	-	-	-	691	100	7
J06BC	Antibacterial monoclonal antibodies	-	-	-	313	100	68
J06BC03	bezlotoxumab	-	-	-	313	100	68
J06BD	Antiviral monoclonal antibodies	-	-	-	537	100	-2
J06BD01	palivizumab	-	-	-	537	100	-2
J07	VACCINES	-	-	-	15 259	7	-29
J07A	BACTERIAL VACCINES	-	-	-	2 454	34	-75
J07AE	Cholera vaccines	-	-	-	50	19	0
J07AE01	cholera, inactivated, whole cell	-	-	-	50	19	0

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J07AG	Haemophilus influenzae B vaccines	-	-	-	20	92	7
J07AG01	haemophilus influenzae B, purified antigen conjugated	-	-	-	20	92	7
J07AH	Meningococcal vaccines	-	-	-	526	87	-57
J07AH08	meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen conjugated	-	-	-	503	88	-57
J07AH09	meningococcus B, multicomponent vaccine	-	-	-	23	63	-30
J07AJ	Pertussis vaccines	-	-	-	92	0	-2
J07AJ52	pertussis, purified antigen, combinations with toxoids	-	-	-	92	0	-2
J07AL	Pneumococcal vaccines	-	-	-	1 393	24	-83
J07AL01	pneumococcus, purified polysaccharides antigen	-	-	-	52	29	-46
J07AL02	pneumococcus, purified polysaccharides antigen conjugated	-	-	-	1 341	23	-83
J07AM	Tetanus vaccines	-	-	-	307	2	19
J07AM51	tetanus toxoid, combinations with diphtheria toxoid	-	-	-	307	2	19
J07AP	Typhoid vaccines	-	-	-	66	22	-8
J07AP01	typhoid, oral, live attenuated	-	-	-	12	4	-56
J07AP03	typhoid, purified polysaccharide antigen	-	-	-	54	26	23
J07B	VIRAL VACCINES	-	-	-	12 792	2	8
J07BA	Encephalitis vaccines	-	-	-	4 553	1	8
J07BA01	encephalitis, tick borne, inactivated, whole virus	-	-	-	4 413	1	9
J07BA02	encephalitis, Japanese, inactivated, whole virus	-	-	-	140	1	0
J07BB	Influenza vaccines	-	-	-	5 091	1	49
J07BB02	influenza, purified antigen	-	-	-	4 952	1	51
J07BB03	influenza, live attenuated	-	-	-	139	0	1
J07BC	Hepatitis vaccines	-	-	-	1 850	8	-46
J07BC01	hepatitis B, purified antigen	-	-	-	519	16	-14
J07BC02	hepatitis A, inactivated, whole virus	-	-	-	323	6	-29
J07BC20	combinations	-	-	-	1 008	5	-58
J07BD	Measles vaccines	-	-	-	52	1	-24
J07BD52	measles, combinations with mumps and rubella, live attenuated	-	-	-	52	1	-24
J07BD54	measles, combinations with mumps, rubella and varicella, live attenuated	-	-	-	0	-	-

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J07BF	Poliomyelitis vaccines	-	-	-	20	20	-17
J07BF03	poliomyelitis, trivalent, inactivated, whole virus	-	-	-	20	20	-17
J07BH	Rota virus diarrhea vaccines	-	-	-	5	0	4
J07BH02	rota virus, pentavalent, live, reassorted	-	-	-	5	0	4
J07BK	Varicella zoster vaccines	-	-	-	746	1	123
J07BK01	varicella, live attenuated	-	-	-	86	2	-10
J07BK02	zoster, live attenuated	-	-	-	180	0	-24
J07BK03	zoster, purified antigen	-	-	-	480	1	-
J07BL	Yellow fever vaccines	-	-	-	85	6	-27
J07BL01	yellow fever, live attenuated	-	-	-	85	6	-27
J07BM	Papillomavirus vaccines	-	-	-	391	3	52
J07BM02	papillomavirus (human types 16, 18)	-	-	-	0	-	-
J07BM03	ppapillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)	-	-	-	391	3	52
J07BX	Other viral vaccines	-	-	-	0	-	-
J07BX03	covid-19 vaccines	-	-	-	0	-	-
J07C	BACTERIAL AND VIRAL VACCINES, COMBINED	-	-	-	13	0	-42
J07CA	Bacterial and viral vaccines, combined	-	-	-	13	0	-42
J07CA02	diphtheria, pertussis, poliomyelitis, tetanus	-	-	-	5	0	-55
J07CA06	diphtheria, Haemophilus influenzae B, pertussis, poliomyelitis, tetanus	-	-	-	8	0	41
J07CA10	typhoid - hepatitis A	-	-	-	0	-	-100
<b>L</b>	<b>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	<b>25,99</b>	<b>13</b>	<b>11</b>	<b>895 574</b>	<b>44</b>	<b>10</b>
L01	ANTINEOPLASTIC AGENTS	0,45	3	-	381 952	68	16
L01A	ALKYLATING AGENTS	-	-	-	6 391	75	3
L01AA	Nitrogen mustard analogues	-	-	-	2 607	97	-7
L01AA01	cyclophosphamide	-	-	-	706	95	-1
L01AA02	chlorambucil	-	-	-	33	13	-65
L01AA03	melphalan	-	-	-	400	96	-12
L01AA05	chlormethine	-	-	-	0	-	-100
L01AA06	ifosfamide	-	-	-	361	100	-20
L01AA09	bendamustine	-	-	-	1 105	100	2
L01AB	Alkyl sulphonates	-	-	-	721	100	12

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01AB01	busulfan	-	-	-	197	100	64
L01AB02	treosulfan	-	-	-	523	100	0
L01AC	Ethylene imines	-	-	-	743	100	61
L01AC01	thiotepa	-	-	-	743	100	61
L01AD	Nitrosoureas	-	-	-	617	100	-3
L01AD01	carmustine	-	-	-	533	100	-3
L01AD02	lomustine	-	-	-	30	94	3
L01AD04	streptozocin	-	-	-	54	100	-6
L01AX	Other alkylating agents	-	-	-	1 704	10	2
L01AX03	temozolomide	-	-	-	1 622	5	1
L01AX04	dacarbazine	-	-	-	82	100	18
L01B	ANTIMETABOLITES	-	-	-	16 331	82	-6
L01BA	Folic acid analogues	-	-	-	6 887	99	8
L01BA01	methotrexate	-	-	-	444	82	5
L01BA04	pemetrexed	-	-	-	6 443	100	9
L01BB	Purine analogues	-	-	-	616	37	15
L01BB02	mercaptopurine	-	-	-	371	4	24
L01BB04	cladribine	-	-	-	64	100	-32
L01BB05	fludarabine	-	-	-	114	71	10
L01BB06	clofarabine	-	-	-	14	100	-64
L01BB07	nelarabine	-	-	-	53	100	1 258
L01BC	Pyrimidine analogues	-	-	-	8 829	72	-16
L01BC01	cytarabine	-	-	-	151	100	-4
L01BC02	fluorouracil	-	-	-	320	99	-21
L01BC05	gemcitabine	-	-	-	651	100	23
L01BC06	capecitabine	-	-	-	800	2	-16
L01BC07	azacitidine	-	-	-	4 922	100	-23
L01BC08	decitabine	-	-	-	257	100	19
L01BC52	fluorouracil, combinations	-	-	-	5	0	-23
L01BC53	tegafur, combinations	-	-	-	96	8	-3
L01BC59	trifluridine, combinations	-	-	-	1 627	0	-5
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	-	-	-	14 658	95	5
L01CA	Vinca alkaloids and analogues	-	-	-	1 067	58	-10

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01CA01	vinblastine	-	-	-	55	100	54
L01CA02	vincristine	-	-	-	248	100	40
L01CA04	vinorelbine	-	-	-	661	33	-18
L01CA05	vinflunine	-	-	-	103	100	-38
L01CB	Podophyllotoxin derivatives	-	-	-	402	72	-11
L01CB01	etoposide	-	-	-	402	72	-11
L01CD	Taxanes	-	-	-	11 772	100	6
L01CD01	paclitaxel	-	-	-	6 689	100	8
L01CD02	docetaxel	-	-	-	726	100	-2
L01CD04	cabazitaxel	-	-	-	4 357	100	5
L01CE	Topoisomerase 1 (TOP1) inhibitors	-	-	-	871	85	25
L01CE01	topotecan	-	-	-	175	30	-5
L01CE02	irinotecan	-	-	-	697	99	35
L01CX	Other plant alkaloids and other natural products	-	-	-	546	100	3
L01CX01	trabectedin	-	-	-	546	100	3
L01D	CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	-	-	-	2 583	100	1
L01DB	Anthracyclines and related substances	-	-	-	2 072	100	-5
L01DB01	doxorubicin	-	-	-	1 421	100	-5
L01DB03	epirubicin	-	-	-	229	100	-17
L01DB06	idarubicin	-	-	-	299	100	12
L01DB07	mitoxantrone	-	-	-	114	99	1
L01DB11	pixantrone	-	-	-	8	100	-74
L01DC	Other cytotoxic antibiotics	-	-	-	511	98	31
L01DC01	bleomycin	-	-	-	151	100	47
L01DC03	mitomycin	-	-	-	360	97	25
L01E	PROTEIN KINASE INHIBITORS	0,45	3	-	101 910	4	12
L01EA	BCR-ABL tyrosine kinase inhibitors	0,12	2	-	9 764	2	-10
L01EA01	imatinib	0,09	1	-	4 031	0	-18
L01EA02	dasatinib	0,01	4	-	1 885	4	-13
L01EA03	nilotinib	0,02	1	-	2 668	1	4
L01EA04	bosutinib	0,00	0	-	444	0	30
L01EA05	ponatinib	0,00	5	-	735	4	-15
L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	0,03	1	-	6 926	1	32



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01EB01	gefitinib	0,00	2	-	65	2	-72
L01EB02	erlotinib	0,00	1	-	144	2	-74
L01EB03	afatinib	0,01	3	-	1 341	2	-26
L01EB04	osimertinib	0,01	1	-	5 375	1	102
L01EC	B-Raf serine-threonine kinase (BRAF) inhibitors	0,00	1	-	6 799	1	17
L01EC01	vemurafenib	0,00	2	-	138	2	-39
L01EC02	dabrafenib	-	-	-	5 006	1	7
L01EC03	encorafenib	0,00	1	-	1 656	1	84
L01ED	Anaplastic lymphoma kinase (ALK) inhibitors	0,01	5	-	3 964	5	10
L01ED01	crizotinib	0,00	8	-	966	5	-17
L01ED03	alectinib	0,01	2	-	2 532	2	23
L01ED04	brigatinib	0,00	63	-	163	62	-27
L01ED05	lorlatinib	0,00	0	-	302	0	117
L01EE	Mitogen-activated protein kinase (MEK) inhibitors	0,02	2	-	4 831	2	31
L01EE01	trametinib	0,01	3	-	3 418	3	18
L01EE03	binimetinib	0,00	1	-	1 413	1	76
L01EF	Cyclin-dependent kinase (CDK) inhibitors	0,09	0	-	17 321	0	19
L01EF01	palbociclib	0,09	0	-	15 952	0	10
L01EF02	ribociclib	0,00	0	-	103	0	36
L01EF03	abemaciclib	0,01	3	-	1 266	2	1 658
L01EG	Mammalian target of rapamycin (mTOR) kinase inhibitors	0,01	2	-	1 495	2	-7
L01EG01	temsirolimus	0,00	100	-	25	100	-59
L01EG02	everolimus	0,01	1	-	1 469	1	-5
L01EH	Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors	0,00	6	-	477	9	9
L01EH01	lapatinib	0,00	1	-	417	1	-4
L01EH02	neratinib	0,00	69	-	60	69	-
L01EJ	Janus-associated kinase (JAK) inhibitors	0,03	18	-	6 561	21	17
L01EJ01	ruxolitinib	0,03	18	-	6 561	21	17
L01EK	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	0,00	0	-	970	0	6
L01EK01	axitinib	0,00	0	-	970	0	6
L01EL	Bruton's tyrosine kinase (BTK) inhibitors	0,04	1	-	14 833	1	15

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01EL01	ibrutinib	0,04	1	-	14 833	1	15
L01EM	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	0,00	8	-	821	10	-20
L01EM01	idelalisib	0,00	1	-	729	1	-29
L01EM03	alpelisib	0,00	73	-	92	79	-
L01EX	Other protein kinase inhibitors	0,09	4	-	27 149	6	9
L01EX01	sunitinib	0,02	2	-	3 203	2	-16
L01EX02	sorafenib	0,01	13	-	1 578	13	-16
L01EX03	pazopanib	0,01	3	-	1 613	2	-21
L01EX04	vandetanib	0,00	67	-	44	67	50
L01EX05	regorafenib	0,00	2	-	708	2	-23
L01EX07	cabozantinib	0,02	3	-	10 078	2	17
L01EX08	lenvatinib	0,01	1	-	1 667	2	51
L01EX09	nintedanib	0,03	1	-	5 298	1	16
L01EX10	midostaurin	0,00	53	-	1 723	53	-5
L01EX12	larotrectinib	0,00	4	-	253	4	195
L01EX13	gilteritinib	0,00	11	-	952	11	700
L01EX22	selpercatinib	0,00	100	-	32	100	-
L01F	MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	-	-	-	188 799	100	16
L01FA	CD20 (Clusters of Differentiation 20) inhibitors	-	-	-	34 449	100	13
L01FA01	rituximab	-	-	-	32 063	100	11
L01FA03	obinutuzumab	-	-	-	2 386	100	63
L01FB	CD22 (Clusters of Differentiation 22) inhibitors	-	-	-	229	100	-43
L01FB01	inotuzumab ozogamicin	-	-	-	229	100	-43
L01FC	CD38 (Clusters of Differentiation 38) inhibitors	-	-	-	11 053	100	79
L01FC01	daratumumab	-	-	-	10 535	100	70
L01FC02	isatuximab	-	-	-	518	100	-
L01FD	HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors	-	-	-	43 841	100	-10
L01FD01	trastuzumab	-	-	-	27 361	100	-12
L01FD02	pertuzumab	-	-	-	9 934	100	-19
L01FD03	trastuzumab emtansine	-	-	-	6 396	100	13
L01FD04	trastuzumab deruxtecan	-	-	-	151	100	-
L01FE	EGFR (Epidermal Growth Factor Receptor) inhibitors	-	-	-	7 053	100	3

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01FE01	cetuximab	-	-	-	2 143	100	2
L01FE02	panitumumab	-	-	-	4 910	100	3
L01FF	PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors	-	-	-	54 923	100	39
L01FF01	nivolumab	-	-	-	15 351	100	24
L01FF02	pembrolizumab	-	-	-	33 503	100	50
L01FF03	durvalumab	-	-	-	1 622	99	88
L01FF04	avelumab	-	-	-	219	100	11 300
L01FF05	atezolizumab	-	-	-	4 094	100	5
L01FF06	cemiplimab	-	-	-	121	100	11
L01FF07	dostarlimab	-	-	-	14	100	-
L01FG	VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors	-	-	-	30 352	100	14
L01FG01	bevacizumab	-	-	-	29 801	100	15
L01FG02	ramucirumab	-	-	-	551	100	0
L01FX	Other monoclonal antibodies and antibody drug conjugates	-	-	-	6 899	100	81
L01FX02	gemtuzumab ozogamicin	-	-	-	43	100	-68
L01FX04	ipilimumab	-	-	-	2 328	100	88
L01FX05	brentuximab vedotin	-	-	-	1 926	100	66
L01FX07	blinatumomab	-	-	-	1 652	100	43
L01FX08	elotuzumab	-	-	-	125	100	200
L01FX09	mogamulizumab	-	-	-	33	100	-
L01FX14	polatuzumab vedotin	-	-	-	792	100	1 104
L01X	OTHER ANTINEOPLASTIC AGENTS	-	-	-	51 280	61	50
L01XA	Platinum compounds	-	-	-	1 315	100	0
L01XA01	cisplatin	-	-	-	254	100	-7
L01XA02	carboplatin	-	-	-	502	100	7
L01XA03	oxaliplatin	-	-	-	558	100	-3
L01XD	Sensitizers used in photodynamic/radiation therapy	-	-	-	947	99	-10
L01XD03	methyl aminolevulinate	-	-	-	730	99	-11
L01XD04	aminolevulinic acid	-	-	-	217	100	-6
L01XF	Retinoids for cancer treatment	-	-	-	336	100	-14
L01XF01	tretinoin	-	-	-	46	100	43

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01XF03	bexarotene	-	-	-	290	100	-19
L01XG	Proteasome inhibitors	-	-	-	17 968	84	1
L01XG01	bortezomib	-	-	-	7 003	100	-12
L01XG02	carfilzomib	-	-	-	8 051	100	7
L01XG03	ixazomib	-	-	-	2 914	3	33
L01XJ	Hedgehog pathway inhibitors	-	-	-	499	3	57
L01XJ01	vismodegib	-	-	-	499	3	57
L01XK	Poly (ADP-ribose) polymerase (PARP) inhibitors	-	-	-	9 588	1	105
L01XK01	olaparib	-	-	-	3 504	1	56
L01XK02	niraparib	-	-	-	6 084	0	150
L01XX	Other antineoplastic agents	-	-	-	12 646	42	52
L01XX05	hydroxycarbamide	-	-	-	476	2	-11
L01XX11	estramustine	-	-	-	1	13	-17
L01XX23	mitotane	-	-	-	196	6	-1
L01XX24	pegaspargase	-	-	-	486	100	-22
L01XX27	arsenic trioxide	-	-	-	357	100	20
L01XX35	anagrelide	-	-	-	221	1	-37
L01XX41	eribulin	-	-	-	1 612	100	19
L01XX44	aflibercept	-	-	-	350	100	18
L01XX51	talimogene laherparepvec	-	-	-	552	100	59
L01XX52	venetoclax	-	-	-	8 394	23	94
L01XY	Combinations of antineoplastic agents	-	-	-	7 982	100	2 082
L01XY01	cytarabine and daunorubicin	-	-	-	284	100	-22
L01XY02	pertuzumab and trastuzumab	-	-	-	7 698	100	-
L02	ENDOCRINE THERAPY	7,78	3	11	72 991	3	4
L02A	HORMONES AND RELATED AGENTS	1,90	4	73	11 772	4	-3
L02AB	Progestogens	0,01	9	3	92	9	3
L02AB02	medroxyprogesterone	0,01	9	3	92	9	3
L02AE	Gonadotrophin releasing hormone analogues	1,88	4	73	11 680	4	-3
L02AE02	leuprorelin	1,30	5	131	7 994	5	-6
L02AE03	goserelin	0,16	4	-11	991	4	-18
L02AE04	triptorelin	0,43	1	24	2 695	1	15
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS	5,88	3	0	61 219	2	5

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L02BA	Anti-estrogens	1,10	2	-9	2 032	8	-44
L02BA01	tamoxifen	0,93	1	-10	453	1	-12
L02BA02	toremifene	0,00	3	15	9	3	15
L02BA03	fulvestrant	0,17	5	-3	1 570	10	-50
L02BB	Anti-androgens	1,48	3	-5	40 221	1	15
L02BB01	flutamide	0,00	3	-10	14	3	-10
L02BB03	bicalutamide	1,29	3	-8	2 676	3	37
L02BB04	enzalutamide	0,18	1	9	35 784	1	9
L02BB05	apalutamid	0,00	1	498	681	1	498
L02BB06	darolutamide	0,01	0	-	1 065	0	2 739
L02BG	Aromatase inhibitors	2,92	1	5	2 379	2	-17
L02BG03	anastrozole	0,22	1	-7	243	3	-13
L02BG04	letrozole	2,40	1	6	1 551	2	-24
L02BG06	exemestane	0,30	2	7	584	2	2
L02BX	Other hormone antagonists and related agents	0,39	24	8	16 587	5	-1
L02BX02	degarelix	0,32	29	11	2 162	22	1
L02BX03	abiraterone	0,07	2	-2	14 425	2	-2
L03	IMMUNOSTIMULANTS	0,66	7	-2	27 498	16	-12
L03A	IMMUNOSTIMULANTS	0,66	7	-2	27 498	16	-12
L03AA	Colony stimulating factors	0,31	12	6	14 053	12	-13
L03AA02	filgrastim	0,05	23	7	2 176	29	-20
L03AA10	lenograstim	0,00	29	-26	21	29	-26
L03AA13	pegfilgrastim	0,19	13	5	8 429	13	-15
L03AA14	lipegfilgrastim	0,07	1	9	3 427	1	-1
L03AB	Interferons	0,26	4	-9	7 080	13	-10
L03AB07	interferon beta-1a	0,20	0	-10	4 084	0	-15
L03AB08	interferon beta-1b	0,02	0	-28	482	0	-32
L03AB11	peginterferon alfa-2a	0,01	99	27	776	99	28
L03AB13	peginterferon beta-1a	0,04	0	1	1 621	0	-5
L03AB15	ropeginterferon alfa-2b	-	-	-	117	100	213
L03AX	Other immunostimulants	0,09	0	-7	6 365	29	-11
L03AX03	BCG vaccine	-	-	-	977	100	7
L03AX13	glatiramer acetate	0,09	0	-7	4 508	0	-14
L03AX16	plerixafor	0,00	100	-14	880	100	-14

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L04	IMMUNOSUPPRESSANTS	17,09	18	8	413 133	31	8
L04A	IMMUNOSUPPRESSANTS	17,09	18	8	413 133	31	8
L04AA	Selective immunosuppressants	2,17	19	7	100 388	46	12
L04AA04	antithymocyte immunoglobulin	0,00	100	42	148	100	42
L04AA06	mycophenolic acid	0,50	3	3	4 847	5	0
L04AA10	sirolimus	0,01	16	33	255	16	32
L04AA13	leflunomide	0,53	2	-6	632	2	3
L04AA18	everolimus	0,00	97	-14	149	97	-14
L04AA23	natalizumab	0,05	100	12	7 902	100	12
L04AA24	abatacept	0,10	33	11	8 065	32	7
L04AA25	eculizumab	0,00	100	-	557	100	-
L04AA26	belimumab	0,01	100	17	562	100	18
L04AA27	fingolimod	0,12	0	-5	11 654	0	-9
L04AA28	belatacept	-	-	-100	0	-	-100
L04AA29	tofacitinib	0,13	2	24	6 438	2	16
L04AA31	teriflunomide	0,15	0	4	7 699	0	0
L04AA32	apremilast	0,08	1	8	3 660	1	2
L04AA33	vedolizumab	0,26	85	21	22 508	93	11
L04AA34	alemtuzumab	0,00	100	-17	69	100	-17
L04AA36	ocrelizumab	0,08	100	31	11 186	100	31
L04AA37	baricitinib	0,07	1	-2	4 154	1	-7
L04AA40	cladribine	0,05	0	34	6 396	0	22
L04AA43	ravulizumab	0,00	100	-	1 721	100	-
L04AA44	upadacitinib	0,03	1	-	1 751	1	646
L04AA45	filgotinib	-	-	-	14	0	-
L04AA52	ofatumumab	-	-	-	20	100	-
L04AB	Tumor necrosis factor alpha (TNF-a) inhibitors	4,68	46	11	161 533	40	-1
L04AB01	etanercept	0,58	0	6	22 092	0	-9
L04AB02	infliximab	2,14	99	11	64 429	100	1
L04AB04	adalimumab	1,22	1	14	44 756	1	-5
L04AB05	certolizumab pegol	0,13	0	5	6 523	0	-1
L04AB06	golimumab	0,61	1	16	23 732	1	7
L04AC	Interleukin inhibitors	1,39	23	34	62 048	21	27
L04AC02	basiliximab	0,00	100	35	513	100	33

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L04AC03	anakinra	0,01	12	10	587	12	9
L04AC05	ustekinumab	0,74	30	34	22 212	25	25
L04AC07	tocilizumab	0,18	49	34	10 710	59	36
L04AC08	canakinumab	0,00	100	100	312	100	100
L04AC10	secukinumab	0,16	0	7	9 883	0	1
L04AC11	siltuximab	0,00	100	-	38	100	-
L04AC12	brodalumab	0,00	0	35	262	0	28
L04AC13	ixekizumab	0,11	0	50	6 710	0	38
L04AC14	sarilumab	0,03	6	61	1 639	6	52
L04AC16	guselkumab	0,09	0	35	5 914	0	27
L04AC18	risankizumab	0,06	1	117	3 237	1	104
L04AC19	satralizumab	-	-	-	31	100	-
L04AD	Calcineurin inhibitors	0,79	5	1	11 371	5	-4
L04AD01	ciclosporin	0,33	3	-8	3 900	3	-12
L04AD02	tacrolimus	0,46	6	9	7 472	6	1
L04AX	Other immunosuppressants	8,05	1	5	77 793	2	12
L04AX01	azathioprine	1,37	1	12	1 021	1	11
L04AX02	thalidomide	0,00	15	-2	71	15	-2
L04AX03	methotrexate	6,26	1	3	10 324	0	8
L04AX04	lenalidomide	0,11	4	6	35 168	4	11
L04AX05	pirfenidone	0,04	1	2	6 100	1	0
L04AX06	pomalidomide	0,02	2	25	10 598	2	28
L04AX07	dimethyl fumarate	0,26	0	19	14 511	0	11
<b>M</b>	<b>MUSCULO-SKELETAL SYSTEM</b>	<b>99,88</b>	<b>2</b>	<b>1</b>	<b>99 602</b>	<b>20</b>	<b>2</b>
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	78,35	2	1	42 307	2	-1
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	78,35	2	1	42 071	2	-1
M01AB	Acetic acid derivatives and related substances	3,58	2	-5	2 012	6	-5
M01AB01	indometacin	0,15	1	-18	122	1	-12
M01AB05	diclofenac	3,37	2	-4	1 781	4	-4
M01AB15	ketorolac	0,02	85	0	49	84	-1
M01AB55	diclofenac, combinations	0,05	0	-9	61	0	-14
M01AC	Oxicams	0,94	2	-9	287	2	-15

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
M01AC06	meloxicam	0,94	2	-9	287	2	-15
M01AE	Propionic acid derivatives	58,64	2	1	32 694	2	0
M01AE01	ibuprofen	50,87	2	2	29 341	1	1
M01AE02	naproxen	5,32	2	-5	1 434	2	2
M01AE03	ketoprofen	0,55	1	-8	391	1	-7
M01AE17	dexketoprofen	0,06	63	9	172	81	6
M01AE51	ibuprofen, combinations	0,31	0	-33	456	0	-34
M01AE52	naproxen and esomeprazole	1,53	1	3	901	1	3
M01AG	Fenamates	0,17	1	-15	71	1	-15
M01AG01	mefenamic acid	0,01	14	-75	4	20	-74
M01AG02	tolfenamic acid	0,16	0	-2	67	0	-2
M01AH	Coxibs	12,24	1	7	2 651	4	-18
M01AH01	celecoxib	0,61	3	0	155	3	-13
M01AH04	parecoxib	0,00	98	-13	53	98	4
M01AH05	etoricoxib	11,63	1	8	2 442	2	-19
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids	2,78	1	-3	4 356	1	0
M01AX01	nabumetone	0,00	3	-83	1	3	-83
M01AX05	glucosamine	2,78	1	-3	1 764	1	-2
M01AX25	chondroitin sulfate	-	-	-	2 591	0	1
M01C	SPECIFIC ANTIRHEUMATIC AGENTS	-	-	-	236	0	13
M01CX	Other specific antirheumatic agents	-	-	-	236	0	13
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	-	-	-	14 574	1	3
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	-	-	-	14 574	1	3
M02AA	Antiinflammatory preparations, non-steroids for topical use	-	-	-	13 764	1	4
M02AA07	piroxicam	-	-	-	846	1	-4
M02AA10	ketoprofen	-	-	-	96	24	0
M02AA13	ibuprofen	-	-	-	1 039	1	37
M02AA15	diclofenac	-	-	-	11 783	0	2
M02AC	Preparations with salicylic acid derivatives	-	-	-	810	5	-7
M03	MUSCLE RELAXANTS	5,09	2	-1	15 956	59	9



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS	-	-	-	10 727	72	10
M03AB	Choline derivatives	-	-	-	561	99	-12
M03AB01	suxamethonium	-	-	-	561	99	-12
M03AC	Other quaternary ammonium compounds	-	-	-	847	98	-22
M03AC09	rocuronium bromide	-	-	-	727	98	-21
M03AC10	mivacurium chloride	-	-	-	15	83	8
M03AC11	cisatracurium	-	-	-	105	100	-32
M03AX	Other muscle relaxants, peripherally acting agents	-	-	-	9 319	69	16
M03AX01	botulinum toxin	-	-	-	9 319	69	16
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	5,09	2	-1	5 229	31	7
M03BC	Ethers, chemically close to antihistamines	2,75	1	0	1 462	28	28
M03BC01	orphenadrine (citrate)	2,52	1	0	1 296	31	26
M03BC51	orphenadrine, combinations	0,22	0	-6	166	0	42
M03BX	Other centrally acting agents	2,34	3	-2	3 767	33	0
M03BX01	baclofen	0,55	9	5	1 716	70	6
M03BX02	tizanidine	1,79	1	-4	2 051	1	-4
M04	ANTIGOUT PREPARATIONS	4,46	2	0	1 490	2	-17
M04A	ANTIGOUT PREPARATIONS	4,46	2	0	1 490	2	-17
M04AA	Preparations inhibiting uric acid production	4,45	2	0	1 474	2	-15
M04AA01	allopurinol	4,12	2	-1	1 208	2	-19
M04AA03	febuxostat	0,32	3	13	266	3	8
M04AC	Preparations with no effect on uric acid metabolism	0,01	22	-69	16	22	-69
M04AC01	colchicine	0,01	22	-69	16	22	-69
M05	DRUGS FOR TREATMENT OF BONE DISEASES	11,97	4	4	18 002	14	6
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	11,97	4	4	18 002	14	6
M05BA	Bisphosphonates	3,16	2	-1	2 871	57	-10
M05BA02	clodronic acid	0,01	1	-21	78	2	-10
M05BA03	pamidronic acid	0,00	100	-29	42	100	-3
M05BA04	alendronic acid	2,28	1	0	700	1	-22
M05BA06	ibandronic acid	0,38	2	0	138	2	-18
M05BA07	risedronic acid	0,49	2	-10	317	3	-5

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
M05BA08	zoledronic acid	0,00	100	106	1 597	99	-5
M05BB	Bisphosphonates, combinations	0,18	1	-8	110	1	-9
M05BB03	alendronic acid and colecalciferol	0,18	1	-8	110	1	-9
M05BC	Bone morphogenetic proteins	-	-	-	67	100	47
M05BC01	dibotermin alfa	-	-	-	67	100	47
M05BX	Other drugs affecting mineralization	8,62	5	7	14 953	5	10
M05BX04	denosumab	8,62	5	7	14 398	5	6
M05BX05	burosumab	-	-	-	555	2	-
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	0,02	54	-25	7 273	99	-1
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	0,02	54	-25	7 273	99	-1
M09AB	Enzymes	-	-	-100	0	-	-100
M09AB02	collagenase clostridium histolyticum	-	-	-100	0	-	-100
M09AX	Other drugs for disorders of the musculo-skeletal system	0,02	54	-25	7 273	99	-1
M09AX01	hyaluronic acid	0,01	34	-32	107	34	-31
M09AX07	nusinersen	0,01	100	0	7 166	100	0
<b>N</b>	<b>NERVOUS SYSTEM</b>	<b>311,08</b>	<b>9</b>	<b>-2</b>	<b>395 935</b>	<b>31</b>	<b>3</b>
N01	ANESTHETICS	-	-	-	17 408	86	1
N01A	ANESTHETICS, GENERAL	-	-	-	7 382	96	-11
N01AB	Halogenated hydrocarbons	-	-	-	2 030	97	-14
N01AB06	isoflurane	-	-	-	11	88	-5
N01AB07	desflurane	-	-	-	285	100	-27
N01AB08	sevoflurane	-	-	-	1 734	96	-12
N01AF	Barbiturates, plain	-	-	-	27	98	-45
N01AF03	thiopental	-	-	-	27	98	-45
N01AH	Opioid anesthetics	-	-	-	1 797	94	5
N01AH01	fentanyl	-	-	-	247	99	5
N01AH02	alfentanil	-	-	-	124	85	-11
N01AH03	sufentanil	-	-	-	30	100	-2
N01AH06	remifentanil	-	-	-	1 395	94	7
N01AX	Other general anesthetics	-	-	-	3 528	95	-15
N01AX03	ketamine	-	-	-	47	93	80

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N01AX10	propofol	-	-	-	2 728	95	-11
N01AX14	esketamine	-	-	-	753	98	-31
N01B	ANESTHETICS, LOCAL	-	-	-	10 026	80	12
N01BB	Amides	-	-	-	9 496	79	11
N01BB01	bupivacaine	-	-	-	601	98	-3
N01BB02	lidocaine	-	-	-	2 307	79	32
N01BB03	mepivacaine	-	-	-	4	14	-10
N01BB04	prilocaine	-	-	-	7	98	417
N01BB09	ropivacaine	-	-	-	1 793	97	15
N01BB10	levobupivacaine	-	-	-	867	96	-11
N01BB20	combinations	-	-	-	1 060	44	2
N01BB51	bupivacaine, combinations	-	-	-	37	88	53
N01BB52	lidocaine, combinations	-	-	-	1 318	80	8
N01BB54	prilocaine, combinations	-	-	-	146	60	-2
N01BB58	articaine, combinations	-	-	-	1 355	66	13
N01BX	Other local anesthetics	-	-	-	531	83	16
N01BX04	capsaicin	-	-	-	531	83	16
N02	ANALGESICS	58,16	5	-4	81 454	11	-1
N02A	OPIOIDS	12,96	8	-4	24 053	25	-3
N02AA	Natural opium alkaloids	2,30	33	9	10 782	47	4
N02AA01	morphine	0,26	90	40	1 393	85	-16
N02AA03	hydromorphone	0,10	67	54	581	73	7
N02AA05	oxycodone	1,65	23	4	5 181	45	5
N02AA55	oxycodone and naloxone	0,29	31	4	3 627	32	13
N02AB	Phenylpiperidine derivatives	0,63	14	-42	3 008	16	-2
N02AB03	fentanyl	0,63	14	-42	3 008	16	-2
N02AE	Oripavine derivatives	1,52	5	2	4 698	6	-8
N02AE01	buprenorphine	1,52	5	2	4 698	6	-8
N02AJ	Opioids in combination with non-opioid analgesics	5,97	1	-5	3 024	1	-6
N02AJ06	codeine and paracetamol	5,41	1	-5	2 522	1	-8
N02AJ08	codeine and ibuprofen	0,10	0	-3	254	0	-4
N02AJ13	tramadol and paracetamol	0,46	1	-1	239	1	15
N02AJ14	taramadol and dexketoprofen	-	-	-	9	0	-1
N02AX	Other opioids	2,54	2	0	2 541	4	-17

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N02AX02	tramadol	2,54	2	0	2 541	4	-17
N02B	OTHER ANALGESICS AND ANTIPYRETICS	41,71	4	-3	29 321	11	-7
N02BA	Salicylic acid and derivatives	1,12	1	-28	2 714	1	-20
N02BA01	acetylsalicylic acid	0,67	1	-9	966	1	-7
N02BA51	acetylsalicylic acid, combinations excl. psycholeptics	0,45	0	-45	1 749	0	-26
N02BE	Anilides	40,59	5	-2	26 359	12	-6
N02BE01	paracetamol	40,46	5	-2	26 002	12	-5
N02BE51	paracetamol, combinations excl. psycholeptics	0,13	0	-38	358	0	-40
N02BG	Other analgesics and antipyretics	0,00	15	15	247	57	30
N02BG09	methoxyflurane	-	-	-	131	95	49
N02BG10	cannabinoids	0,00	15	15	116	15	15
N02C	ANTIMIGRAINE PREPARATIONS	3,50	0	-22	28 081	0	8
N02CC	Selective 5HT1-receptor agonists	2,51	1	-32	7 700	1	-2
N02CC01	sumatriptan	1,59	1	-43	4 557	2	-3
N02CC02	naratriptan	0,03	0	3	76	0	-4
N02CC03	zolmitriptan	0,19	1	2	793	1	-8
N02CC04	rizatriptan	0,16	0	10	769	0	10
N02CC05	almotriptan	0,11	0	0	502	0	14
N02CC06	eletriptan	0,26	0	8	419	0	-13
N02CC07	frovatriptan	0,17	0	3	583	0	-2
N02CD	Calcitonin gene-related peptide (CGRP) antagonists	0,98	0	23	20 381	0	13
N02CD01	erenumab	0,62	0	-1	10 209	0	-23
N02CD02	galcanezumab	0,10	0	814	2 633	0	813
N02CD03	fremanezumab	0,27	0	69	7 539	0	69
N03	ANTIEPILEPTICS	25,17	4	4	47 344	8	-1
N03A	ANTIEPILEPTICS	25,17	4	4	47 344	8	-1
N03AB	Hydantoin derivatives	0,13	10	-10	657	86	-9
N03AB02	phenytoin	0,13	6	-10	96	6	-10
N03AB05	fosphenytoin	0,00	100	-13	561	100	-9
N03AE	Benzodiazepine derivatives	0,59	2	-8	434	2	-8
N03AE01	clonazepam	0,59	2	-8	434	2	-8
N03AF	Carboxamide derivatives	3,50	2	-2	4 900	2	-2

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N03AF01	carbamazepine	1,18	2	-6	1 007	4	-8
N03AF02	oxcarbazepine	2,23	2	-1	3 165	2	0
N03AF03	rufinamide	0,02	3	7	251	3	7
N03AF04	eslicarbazepine	0,06	1	-1	477	1	-1
N03AG	Fatty acid derivatives	3,50	5	-2	4 552	9	-3
N03AG01	valproic acid	3,48	5	-2	4 474	9	-3
N03AG04	vigabatrin	0,02	10	-7	78	10	-6
N03AX	Other antiepileptics	17,46	4	7	36 801	8	-1
N03AX09	lamotrigine	2,41	2	4	4 517	2	-1
N03AX11	topiramate	0,34	4	-5	1 423	4	-5
N03AX12	gabapentin	4,72	5	11	6 824	5	4
N03AX14	levetiracetam	2,83	5	2	8 168	9	-6
N03AX15	zonisamide	0,19	2	-3	801	2	-4
N03AX16	pregabalin	5,89	3	6	5 241	4	-20
N03AX17	stiripentol	0,01	2	0	338	2	-1
N03AX18	lacosamide	0,67	6	10	6 050	19	9
N03AX22	perampanel	0,10	5	10	1 021	7	7
N03AX23	brivaracetam	0,28	3	44	1 968	9	30
N03AX24	cannabidiol	0,00	6	-	448	6	-
N04	ANTI-PARKINSON DRUGS	5,22	4	3	16 353	4	-3
N04A	ANTICHOLINERGIC AGENTS	0,16	5	-4	87	5	-4
N04AA	Tertiary amines	0,16	5	-4	87	5	-4
N04AA02	biperiden	0,16	5	-4	87	5	-4
N04B	DOPAMINERGIC AGENTS	5,06	4	3	16 265	4	-3
N04BA	Dopa and dopa derivatives	2,53	5	10	13 076	4	0
N04BA02	levodopa and decarboxylase inhibitor	1,84	5	15	9 853	3	-9
N04BA03	levodopa, decarboxylase inhibitor and COMT inhibitor	0,69	5	-3	3 223	5	42
N04BC	Dopamine agonists	1,43	2	-2	2 524	3	-15
N04BC01	bromocriptine	0,00	27	-92	0	27	-92
N04BC04	ropinirole	0,64	2	-5	331	2	-29
N04BC05	pramipexole	0,69	3	3	1 347	2	-11
N04BC06	cabergoline	0,01	6	-1	74	6	-1
N04BC07	apomorphine	0,01	3	-29	250	3	-30

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N04BC09	rotigotine	0,08	3	-8	521	3	-8
N04BD	Monoamine oxidase type B inhibitors	1,06	3	-4	460	3	-8
N04BD01	selegiline	0,71	3	-2	325	3	-5
N04BD02	rasagiline	0,35	4	-6	134	4	-15
N04BD03	safinamide	0,00	0	84	1	0	25
N04BX	Other dopaminergic agents	0,03	5	21	205	5	21
N04BX02	entacapone	0,03	6	3	174	6	3
N04BX04	opicapone	0,00	4	-	31	4	-
N05	PSYCHOLEPTICS	86,95	5	1	74 115	14	2
N05A	ANTIPSYCHOTICS	23,13	7	3	52 700	10	2
N05AA	Phenothiazines with aliphatic side chain	0,28	6	-7	337	6	-3
N05AA02	levomepromazine	0,28	6	-7	337	6	-3
N05AB	Phenothiazines with piperazine structure	0,42	5	9	551	5	-3
N05AB03	perphenazine	0,41	5	10	530	5	-3
N05AB04	prochlorperazine	0,01	2	6	20	2	6
N05AD	Butyrophenone derivatives	0,39	24	4	420	43	-16
N05AD01	haloperidol	0,38	22	6	336	29	-7
N05AD08	droperidol	0,01	97	-40	84	97	-40
N05AE	Indole derivatives	0,35	5	6	1 643	6	6
N05AE03	sertindole	0,06	4	-6	363	5	-6
N05AE04	ziprasidone	0,16	3	-2	580	3	-2
N05AE05	lurasidone	0,13	9	27	700	9	22
N05AF	Thioxanthene derivatives	0,60	9	5	553	14	-5
N05AF01	flupentixol	0,05	2	-6	69	3	0
N05AF03	chlorprothixene	0,22	3	-8	230	3	-7
N05AF05	zuclopenthixol	0,33	14	18	254	27	-3
N05AH	Diazepines, oxazepines, thiazepines and oxepines	14,53	7	0	20 494	11	2
N05AH02	clozapine	2,32	10	-2	3 530	9	-9
N05AH03	olanzapine	6,70	8	1	12 562	15	2
N05AH04	quetiapine	5,50	3	0	4 294	3	13
N05AH05	asenapine	0,02	10	-5	107	13	-6
N05AL	Benzamides	0,04	7	-9	93	7	-9
N05AL01	sulpiride	0,04	7	-9	93	7	-9
N05AN	Lithium	0,99	6	1	626	6	1

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N05AN01	lithium	0,99	6	1	626	6	1
N05AX	Other antipsychotics	5,52	7	13	27 985	9	2
N05AX08	risperidone	1,80	6	2	7 928	5	-9
N05AX12	aripiprazole	2,87	6	6	8 563	10	4
N05AX13	paliperidone	0,67	11	74	10 560	11	3
N05AX15	cariprazine	0,11	25	329	524	22	266
N05AX16	brexpiprazole	0,06	17	460	410	16	429
N05B	ANXIOLYTICS	14,50	6	-6	7 082	30	2
N05BA	Benzodiazepine derivatives	13,09	6	-7	5 748	35	3
N05BA01	diazepam	3,60	8	-9	1 136	23	-14
N05BA04	oxazepam	4,52	4	-4	1 646	4	-3
N05BA06	lorazepam	1,73	14	-3	2 065	82	31
N05BA09	clobazam	0,39	4	3	133	4	3
N05BA12	alprazolam	2,86	1	-11	768	1	-14
N05BB	Diphenylmethane derivatives	1,14	4	-5	682	4	-6
N05BB01	hydroxyzine	1,14	4	-5	682	4	-6
N05BE	Azaspirodecanedione derivatives	0,27	11	8	653	11	8
N05BE01	buspirone	0,27	11	8	653	11	8
N05C	HYPNOTICS AND SEDATIVES	49,32	4	3	14 332	21	0
N05CD	Benzodiazepine derivatives	4,83	7	-9	3 345	17	-5
N05CD02	nitrazepam	0,14	1	-47	53	1	-48
N05CD05	triazolam	0,03	1	-12	29	1	-12
N05CD07	temazepam	4,45	4	-7	1 832	3	2
N05CD08	midazolam	0,21	60	-9	1 431	35	-9
N05CF	Benzodiazepine related drugs	14,80	2	-8	2 328	2	-7
N05CF01	zopiclone	10,56	3	-8	1 720	2	-9
N05CF02	zolpidem	4,24	1	-8	608	1	-2
N05CH	Melatonin receptor agonists	29,49	4	12	6 045	4	7
N05CH01	melatonin	29,49	4	12	6 045	4	7
N05CM	Other hypnotics and sedatives	0,21	7	-7	2 614	84	1
N05CM09	Valerianae radix	0,19	0	-7	416	0	-8
N05CM18	dexmedetomidine	0,01	100	-1	2 198	100	2
N06	PSYCHOANALEPTICS	111,06	2	5	64 561	3	10
N06A	ANTIDEPRESSANTS	85,24	2	5	38 187	3	6

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N06AA	Non-selective monoamine reuptake inhibitors	3,94	2	1	3 600	2	5
N06AA04	clomipramine	0,21	5	-2	158	5	-2
N06AA06	trimipramine	0,08	2	-11	58	2	-11
N06AA09	amitriptyline	3,00	2	0	2 891	2	5
N06AA10	nortriptyline	0,65	2	7	493	2	13
N06AB	Selective serotonin reuptake inhibitors	46,45	1	4	7 165	2	5
N06AB03	fluoxetine	4,91	2	9	1 210	2	11
N06AB04	citalopram	8,08	1	-5	1 287	2	-4
N06AB05	paroxetine	2,31	1	-1	570	1	-13
N06AB06	sertraline	11,93	2	10	1 676	2	4
N06AB08	fluvoxamine	0,13	1	-4	73	1	-4
N06AB10	escitalopram	19,08	1	5	2 348	2	15
N06AG	Monoamine oxidase type A inhibitors	0,33	1	-2	260	1	-3
N06AG02	moclobemide	0,33	1	-2	260	1	-3
N06AX	Other antidepressants	34,53	2	6	27 163	3	6
N06AX03	mianserin	0,20	3	-2	180	3	-5
N06AX05	trazodone	0,21	2	5	188	2	5
N06AX11	mirtazapine	8,55	3	1	5 277	4	4
N06AX12	bupropion	2,69	1	6	3 204	1	-21
N06AX16	venlafaxine	11,90	2	2	7 016	2	0
N06AX17	milnacipran	-	-	-100	0	-	-100
N06AX18	reboxetin	-	-	-100	0	-	-100
N06AX21	duloxetine	4,49	2	8	2 049	3	57
N06AX22	agomelatine	1,10	2	6	727	3	-7
N06AX26	vortioxetine	5,40	2	23	8 279	2	21
N06AX27	esketamine	0,00	91	-	243	91	438
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	8,61	1	28	20 090	2	25
N06BA	Centrally acting sympathomimetics	8,56	1	29	19 621	1	26
N06BA02	dexamfetamine	0,17	1	13	817	1	10
N06BA04	methylphenidate	6,21	1	26	9 931	1	23
N06BA07	modafinil	0,09	1	4	772	1	1
N06BA09	atomoxetine	0,24	4	21	836	5	-5
N06BA12	lisdexamfetamine	1,85	1	45	7 253	1	43



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N06BA14	solriamfetol	-	-	-	13	0	-
N06BC	Xanthine derivatives	0,00	100	10	277	100	10
N06BC01	caffeine	0,00	100	10	277	100	10
N06BX	Other psychostimulants and nootropics	0,05	1	0	192	6	-36
N06BX03	piracetam	0,05	1	1	53	1	1
N06BX13	idebenone	0,00	8	-39	140	8	-44
N06C	PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	0,68	1	-29	421	1	-4
N06CA	Antidepressants in combination with psycholeptics	0,68	1	-29	421	1	-4
N06CA01	amitriptyline and psycholeptics	0,68	1	-29	421	1	-4
N06D	ANTI-DEMENTIA DRUGS	16,52	4	-1	5 862	5	0
N06DA	Anticholinesterases	9,58	3	-3	4 516	4	1
N06DA02	donepezil	5,52	3	-7	733	3	13
N06DA03	rivastigmine	2,31	4	1	2 538	6	3
N06DA04	galantamine	1,75	3	5	1 245	3	-7
N06DX	Other anti-dementia drugs	6,94	4	1	1 347	5	-5
N06DX01	memantine	6,94	4	1	1 347	5	-5
N07	OTHER NERVOUS SYSTEM DRUGS	24,52	76	-33	94 700	86	7
N07A	PARASYMPATHOMIMETICS	0,27	5	2	448	36	-8
N07AA	Anticholinesterases	0,27	5	2	437	37	-8
N07AA02	pyridostigmine	0,27	3	3	279	3	3
N07AA51	neostigmine, combinations	0,01	98	-24	158	98	-23
N07AX	Other parasympathomimetics	0,00	5	-29	11	5	-7
N07AX01	pilocarpine	0,00	5	-29	11	5	-7
N07B	DRUGS USED IN ADDICTIVE DISORDERS	21,35	87	-37	91 548	89	7
N07BA	Drugs used in nicotine dependence	19,07	89	-40	76 475	89	2
N07BA01	nicotine	18,83	90	-40	75 207	91	5
N07BA03	varenicline	0,24	1	-63	1 268	1	-63
N07BB	Drugs used in alcohol dependence	0,58	6	-7	567	5	-6
N07BB01	disulfiram	0,49	6	-8	366	6	-8
N07BB04	naltrexone	0,09	5	0	156	5	0
N07BB05	nalmefene	0,01	0	-14	44	0	-15
N07BC	Drugs used in opioid dependence	1,69	86	60	14 507	91	52
N07BC01	buprenorphine	0,78	95	219	10 512	95	42

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N07BC02	methadone	0,51	82	-16	1 350	87	-15
N07BC05	levomethadone	0,08	66	330	321	67	331
N07BC51	buprenorphine, combinations	0,32	72	71	2 323	75	365
N07C	ANTIVERTIGO PREPARATIONS	2,82	1	1	666	1	-6
N07CA	Antivertigo preparations	2,82	1	1	666	1	-6
N07CA01	betahistine	2,82	1	1	666	1	-6
N07CA52	cinnarizine, combinations	0,00	0	-94	0	0	-94
N07X	OTHER NERVOUS SYSTEM DRUGS	0,07	3	14	2 037	6	-10
N07XX	Other nervous system drugs	0,07	3	14	2 037	6	-10
N07XX02	riluzole	0,02	8	0	255	8	21
N07XX04	sodium oxybate	0,03	1	4	605	1	-45
N07XX06	tetrabenazine	0,00	7	-11	56	7	-11
N07XX07	fampridine	0,01	3	13	106	5	-1
N07XX08	tafamidis	0,00	5	155	807	10	23
N07XX11	pitolisant	0,01	0	140	209	0	75
<b>P</b>	<b>ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</b>	<b>2,43</b>	<b>2</b>	<b>-4</b>	<b>6 362</b>	<b>4</b>	<b>10</b>
P01	ANTIPROTOZOALS	2,18	3	-3	2 501	5	-7
P01A	AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES	0,27	13	-2	637	11	-8
P01AB	Nitroimidazole derivatives	0,27	13	-2	637	11	-8
P01AB01	metronidazole	0,27	13	-2	637	11	-8
P01B	ANTIMALARIALS	1,91	1	-4	1 864	3	-7
P01BA	Aminoquinolines	1,90	1	-4	1 691	1	-4
P01BA02	hydroxychloroquine	1,90	1	-4	1 691	1	-4
P01BB	Biguanides	0,01	23	-29	136	23	-37
P01BB51	proguanil and atovaquone	0,01	23	-29	136	23	-37
P01BC	Quinine alkaloids	0,00	1	0	37	1	-1
P01BC02	mefloquine	0,00	1	0	37	1	-1
P02	ANTHELMINTICS	0,25	1	-7	1 927	5	27
P02C	ANTINEMATODAL AGENTS	0,25	1	-7	1 927	5	27
P02CF	Avermectines	0,01	15	-	557	15	-
P02CF01	ivermectin	0,01	15	-	557	15	-
P02CX	Other antinematodals	0,24	0	-9	1 370	0	-10

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
P02CX01	pyrvinium	0,24	0	-9	1 370	0	-10
P03	ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS	-	-	-	1 933	4	23
P03A	ECTOPARASITICIDES, INCL. SCABICIDES	-	-	-	1 933	4	23
P03AC	Pyrethrines, incl. synthetic compounds	-	-	-	1 933	4	23
P03AC04	permethrin	-	-	-	1 933	4	23
<b>R</b>	<b>RESPIRATORY SYSTEM</b>	<b>198,17</b>	<b>2</b>	<b>6</b>	<b>150 940</b>	<b>4</b>	<b>2</b>
R01	NASAL PREPARATIONS	33,72	1	1	24 117	1	1
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	32,61	1	2	19 940	1	1
R01AA	Sympathomimetics, plain	9,57	1	4	5 349	1	1
R01AA05	oxymetazoline	0,73	0	-3	253	0	-3
R01AA07	xylometazoline	8,84	1	5	5 097	1	1
R01AB	Sympathomimetics, combinations excl. corticosteroids	0,69	0	7	517	0	5
R01AB06	xylometazoline	0,69	0	7	517	0	5
R01AC	Antiallergic agents, excl. corticosteroids	0,29	0	36	351	0	43
R01AC01	cromoglicic acid	-	-	-100	0	-	-100
R01AC02	levocabastine	0,14	0	55	212	0	55
R01AC03	azelastine	0,15	0	58	138	0	58
R01AD	Corticosteroids	21,74	1	0	13 264	1	0
R01AD01	beclometasone	0,99	0	-5	527	0	-1
R01AD05	budesonide	-	-	-100	0	-	-100
R01AD08	fluticasone	4,39	1	-1	2 369	1	0
R01AD09	mometasone	6,10	1	4	1 891	1	1
R01AD11	triamcinolone	0,68	0	2	548	0	2
R01AD12	fluticasone furoate	4,61	1	-1	2 763	1	-3
R01AD58	fluticasone, combinations	4,95	0	4	5 166	0	2
R01AX	Other nasal preparations	0,32	4	3	459	16	2
R01AX03	ipratropium bromide	0,11	6	-13	183	8	-1
R01AX06	mupirocin	-	-	-	162	33	0
R01AX10	various	0,21	3	13	114	3	13
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE	1,12	1	-27	4 177	1	3
R01BA	Sympathomimetics	1,12	1	-27	4 177	1	3

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R01BA01	phenylpropanolamine	0,13	5	-2	49	5	-3
R01BA52	pseudoephedrine, combinations	0,99	1	-29	4 128	1	3
R02	THROAT PREPARATIONS	2,28	0	-9	5 375	1	-6
R02A	THROAT PREPARATIONS	2,28	0	-9	5 375	1	-6
R02AA	Antiseptics	1,12	0	5	3 013	0	1
R02AA03	dichlorobenzyl alcohol	1,11	0	6	2 782	0	6
R02AA05	chlorhexidine	0,00	0	-64	4	0	-65
R02AA20	various	-	-	-	227	2	-33
R02AB	Antibiotics	0,88	1	-17	1 854	1	-10
R02AB30	gramicidin	0,88	1	-17	1 854	1	-10
R02AX	Other throat preparations	0,29	0	-25	508	0	-24
R02AX01	flurbiprofen	0,03	0	-18	132	0	-22
R02AX03	benzydamine	0,26	0	-26	376	0	-25
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	80,99	3	6	90 256	5	-4
R03A	ADRENERGICS, INHALANTS	47,12	3	12	54 499	3	-3
R03AC	Selective beta-2-adrenoceptor agonists	14,13	4	91	6 976	3	-8
R03AC02	salbutamol	12,03	4	111	4 968	3	-7
R03AC03	terbutaline	1,03	1	102	457	1	-12
R03AC12	salmeterol	0,31	1	-9	433	1	-10
R03AC13	formoterol	0,60	2	-8	883	2	-9
R03AC18	indacaterol	0,10	2	-19	130	2	-19
R03AC19	olodaterol	0,06	3	-2	105	3	-2
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	29,31	2	-6	36 196	2	-5
R03AK06	salmeterol and fluticasone	6,66	3	-26	7 489	4	-24
R03AK07	formoterol and budesonide	13,76	2	-4	14 353	2	-5
R03AK08	formoterol and beclometasone	4,27	2	12	5 034	2	12
R03AK10	vilanterol and fluticasone furoate	3,17	1	9	7 136	1	12
R03AK11	formoterol and fluticasone	1,46	2	26	2 181	2	-8
R03AK14	indacaterol and mometasone	-	-	-	3	0	205
R03AL	Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids	3,67	9	9	11 327	6	12
R03AL01	fenoterol and ipratropium bromide	0,55	22	-2	286	24	-7

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R03AL02	salbutamol and ipratropium bromide	0,19	38	-21	182	38	-35
R03AL03	vilanterol and umeclidinium bromide	0,39	3	0	1 165	3	0
R03AL04	indacaterol and glycopyrronium bromide	0,12	3	-8	339	3	-8
R03AL05	formoterol and acclidinium bromide	0,04	2	-14	122	2	-14
R03AL06	olodaterol and tiotropium bromide	0,79	5	-4	2 243	5	-4
R03AL07	formoterol and glycopyrronium bromide	0,01	6	58	33	6	58
R03AL08	vilanterol, umeclidinium bromide and fluticasone furoate	0,78	3	17	2 874	3	11
R03AL09	formoterol, glycopyrronium bromide and beclometasone	0,80	9	59	3 969	7	38
R03AL11	formoterol, glycopyrronium bromide and budesonide	-	-	-	87	2	-
R03AL12	indacaterol, glycopyrronium bromide and mometasone	0,01	0	2 220	26	0	2 202
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS	24,69	3	-3	25 489	3	-10
R03BA	Glucocorticoids	18,84	2	-7	15 285	3	-11
R03BA01	beclometasone	2,28	3	-10	2 125	3	-12
R03BA02	budesonide	4,08	3	-12	4 114	4	-13
R03BA05	fluticasone	5,07	3	-10	5 418	2	-13
R03BA07	mometasone	0,13	1	-15	124	1	-17
R03BA08	ciclesonide	7,27	1	0	3 505	1	-4
R03BB	Anticholinergics	5,85	7	11	10 204	4	-8
R03BB01	ipratropium bromide	0,46	43	-43	239	40	-15
R03BB04	tiotropium bromide	5,07	4	24	9 297	4	-8
R03BB05	acclidinium bromide	0,03	3	-18	61	3	-18
R03BB06	glycopyrronium bromide	0,07	2	-13	133	2	-13
R03BB07	umeclidinium bromide	0,23	2	-5	474	2	-5
R03C	ADRENERGICS FOR SYSTEMIC USE	0,03	1	2	80	1	8
R03CC	Selective beta-2-adrenoceptor agonists	0,03	1	2	80	1	8
R03CC02	salbutamol	0,03	1	2	80	1	8
R03D	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	9,16	2	0	10 189	20	6
R03DA	Xanthines	0,59	4	-9	144	4	-26

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R03DA04	theophylline	0,59	4	-9	144	4	-25
R03DA05	aminophylline	-	-	-100	0	-	-100
R03DA54	theophylline, combinations excl. psycholeptics	-	-	-100	0	-	-100
R03DC	Leukotriene receptor antagonists	8,37	1	1	1 336	1	3
R03DC03	montelukast	8,37	1	1	1 336	1	3
R03DX	Other systemic drugs for obstructive airway diseases	0,20	16	5	8 708	23	8
R03DX05	omalizumab	0,06	30	14	3 741	30	12
R03DX07	roflumilast	0,08	4	-10	197	5	-9
R03DX08	reslizumab	0,00	100	-43	102	100	-43
R03DX09	mepolizumab	0,04	14	27	3 043	14	10
R03DX10	benralizumab	0,02	21	14	1 626	21	3
R05	COUGH AND COLD PREPARATIONS	2,65	2	-22	6 175	2	-13
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	1,58	3	-17	2 604	5	-15
R05CA	Expectorants	0,06	0	-22	111	0	-1
R05CA10	combinations	0,06	0	-22	111	0	-1
R05CB	Mucolytics	1,52	3	-17	2 494	5	-16
R05CB01	acetylcysteine	0,40	1	-23	452	4	-19
R05CB02	bromhexine	0,59	0	-18	785	0	-19
R05CB03	carbocisteine	0,03	1	-16	49	1	-15
R05CB06	ambroxol	0,14	4	-21	335	4	-22
R05CB13	dornase alfa (desoxyribonuclease)	0,01	10	-2	380	10	-2
R05CB15	erdosteine	0,35	11	-5	492	11	-12
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	0,59	1	-14	1 336	1	-14
R05DA	Opium alkaloids and derivatives	0,52	1	-9	1 123	1	-7
R05DA01	ethylmorphine	0,11	1	-32	495	1	-15
R05DA09	dextromethorphan	0,42	1	0	628	1	1
R05DB	Other cough suppressants	0,07	0	-40	213	0	-41
R05DB05	pentoxyverine	0,07	0	-40	213	0	-41
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	0,47	0	-41	1 660	0	-16
R05FA	Opium derivatives and expectorants	0,21	0	-56	547	0	-7

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R05FA02	opium derivatives and expectorants	0,21	0	-56	547	0	-7
R05FB	Other cough suppressants and expectorants	0,27	0	-19	1 113	0	-19
R05FB02	cough suppressants and expectorants	0,27	0	-19	1 113	0	-19
R05X	OTHER COLD PREPARATIONS	-	-	-	575	0	16
R06	ANTIHISTAMINES FOR SYSTEMIC USE	78,51	1	10	18 361	1	7
R06A	ANTIHISTAMINES FOR SYSTEMIC USE	78,51	1	10	18 361	1	7
R06AA	Aminoalkyl ethers	0,12	2	13	159	2	16
R06AA09	doxylamine	0,12	2	13	159	2	16
R06AE	Piperazine derivatives	40,78	2	7	9 926	1	6
R06AE03	cyclizine	0,01	0	128	35	0	152
R06AE05	meclozine	0,08	1	-4	235	1	0
R06AE07	cetirizine	35,55	2	8	8 215	1	8
R06AE09	levocetirizine	5,14	0	3	1 442	0	-4
R06AX	Other antihistamines for systemic use	37,62	0	13	8 275	0	8
R06AX13	loratadine	3,39	0	-4	725	0	-3
R06AX18	acrivastine	0,08	0	6	153	0	6
R06AX22	ebastine	10,10	0	10	2 677	0	5
R06AX26	fexofenadine	4,94	0	17	1 863	0	8
R06AX27	desloratadine	18,67	0	17	2 658	1	14
R06AX29	bilastine	0,44	0	6	200	0	7
R07	OTHER RESPIRATORY SYSTEM PRODUCTS	0,00	21	334	6 656	13	548
R07A	OTHER RESPIRATORY SYSTEM PRODUCTS	0,00	21	334	6 656	13	548
R07AA	Lung surfactants	0,00	100	5	864	100	1
R07AA02	natural phospholipids	0,00	100	5	864	100	1
R07AX	Other respiratory system products	0,00	0	2 567	5 792	0	3 301
R07AX02	ivacaftor	0,00	0	2 567	2 014	0	2 265
R07AX30	ivacaftor and lumacaftor	-	-	-	644	0	-
R07AX31	ivacaftor and tezacaftor	-	-	-	71	0	-17
R07AX32	ivacaftor, tezacaftor and elexacaftor	-	-	-	3 064	0	-
<b>S</b>	<b>SENSORY ORGANS</b>	<b>31,80</b>	<b>2</b>	<b>19</b>	<b>71 271</b>	<b>45</b>	<b>4</b>
S01	OPHTHALMOLOGICALS	31,80	2	19	69 199	46	4
S01A	ANTIINFECTIVES	-	-	-	3 601	18	-5
S01AA	Antibiotics	-	-	-	2 953	19	-5
S01AA01	chloramphenicol	-	-	-	2 576	17	-4

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
S01AA12	tobramycin	-	-	-	15	23	4
S01AA13	fusidic acid	-	-	-	208	7	-24
S01AA26	azithromycin	-	-	-	28	1	-8
S01AA27	cefuroxime	-	-	-	126	84	23
S01AD	Antivirals	-	-	-	49	7	44
S01AD03	aciclovir	-	-	-	49	7	44
S01AE	Fluoroquinolones	-	-	-	599	13	-9
S01AE01	ofloxacin	-	-	-	67	32	-16
S01AE05	levofloxacin	-	-	-	518	9	-8
S01AE07	moxifloxacin	-	-	-	14	41	4
S01B	ANTIINFLAMMATORY AGENTS	-	-	-	4 030	38	5
S01BA	Corticosteroids, plain	-	-	-	3 033	50	0
S01BA01	dexamethasone	-	-	-	1 616	71	2
S01BA02	hydrocortisone	-	-	-	130	1	15
S01BA04	prednisolone	-	-	-	778	3	-9
S01BA05	triamcinolone	-	-	-	277	99	-2
S01BA07	fluorometholone	-	-	-	177	1	-12
S01BA15	fluocinolone acetonide	-	-	-	55	100	-
S01BC	Antiinflammatory agents, non-steroids	-	-	-	998	2	24
S01BC03	diclofenac	-	-	-	86	12	-8
S01BC10	nepafenac	-	-	-	827	1	28
S01BC11	bromfenac	-	-	-	85	0	33
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	-	-	-	1 390	16	26
S01CA	Corticosteroids and antiinfectives in combination	-	-	-	1 390	16	26
S01CA01	dexamethasone and antiinfectives	-	-	-	1 139	17	38
S01CA03	hydrocortisone and antiinfectives	-	-	-	251	11	-8
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	31,80	2	19	14 405	3	-1
S01EA	Sympathomimetics in glaucoma therapy	0,55	10	-5	446	37	6
S01EA03	apraclonidine	0,05	62	12	189	80	28
S01EA05	brimonidine	0,51	5	-7	256	5	-7
S01EB	Parasympathomimetics	0,10	15	-3	41	54	0
S01EB01	pilocarpine	0,10	15	-3	16	15	-3



## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
S01EB09	acetylcholine	-	-	-	25	79	1
S01EC	Carbonic anhydrase inhibitors	2,93	3	2	1 405	3	1
S01EC03	dorzolamide	0,17	4	-2	111	4	-8
S01EC04	brinzolamide	2,15	3	2	770	3	1
S01EC54	brinzolamide, combinations	0,60	2	3	523	2	3
S01ED	Beta blocking agents	16,45	1	43	7 071	2	2
S01ED01	timolol	0,22	5	-56	275	2	-4
S01ED02	betaxolol	0,29	3	-3	75	3	-3
S01ED51	timolol, combinations	15,94	1	49	6 721	2	2
S01EE	Prostaglandin analogues	11,77	2	0	5 442	2	-6
S01EE01	latanoprost	5,15	2	1	1 643	2	-17
S01EE03	bimatoprost	3,84	1	0	884	2	-3
S01EE04	travoprost	0,72	3	-9	622	2	-9
S01EE05	tafluprost	2,06	1	2	2 293	1	3
S01F	MYDRIATICS AND CYCLOPLEGICS	-	-	-	819	60	25
S01FA	Anticholinergics	-	-	-	736	59	29
S01FA01	atropine	-	-	-	38	33	4
S01FA04	cyclopentolate	-	-	-	125	41	10
S01FA06	tropicamide	-	-	-	294	52	4
S01FA56	tropicamide, combinations	-	-	-	279	78	100
S01FB	Sympathomimetics excl. antiglaucoma preparations	-	-	-	84	70	0
S01FB01	phenylephrine	-	-	-	84	70	0
S01G	DECONGESTANTS AND ANTIALLERGICS	-	-	-	3 970	1	20
S01GA	Sympathomimetics used as decongestants	-	-	-	212	0	5
S01GA02	tetryzoline	-	-	-	212	0	5
S01GX	Other antiallergics	-	-	-	3 758	1	21
S01GX01	cromoglicic acid	-	-	-	2 660	1	15
S01GX02	levocabastine	-	-	-	257	0	46
S01GX05	lodoxamide	-	-	-	44	0	24
S01GX06	emedastine	-	-	-	34	0	26
S01GX08	ketotifen	-	-	-	696	1	35
S01GX09	olopatadine	-	-	-	68	0	31
S01H	LOCAL ANESTHETICS	-	-	-	232	73	-6

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
S01HA	Local anesthetics	-	-	-	232	73	-6
S01HA02	oxybuprocaine	-	-	-	232	73	-6
S01J	DIAGNOSTIC AGENTS	-	-	-	210	59	2
S01JA	Colouring agents	-	-	-	210	59	2
S01JA01	fluorescein	-	-	-	18	98	7
S01JA51	fluorescein, combinations	-	-	-	192	55	1
S01L	OCULAR VASCULAR DISORDER AGENTS	-	-	-	28 026	100	5
S01LA	Antineovascularisation agents	-	-	-	28 026	100	5
S01LA01	verteporfin	-	-	-	0	-	-100
S01LA04	ranibizumab	-	-	-	250	100	-16
S01LA05	aflibercept	-	-	-	27 726	100	6
S01LA06	brolocizumab	-	-	-	50	100	-7
S01X	OTHER OPHTHALMOLOGICALS	-	-	-	12 516	3	5
S01XA	Other ophthalmologicals	-	-	-	12 516	3	5
S01XA02	retinol	-	-	-	507	3	-4
S01XA18	ciclosporin	-	-	-	740	1	12
S01XA20	artificial tears and other indifferent preparations	-	-	-	11 186	3	4
S01XA21	mercaptamine	-	-	-	84	5	65
S02	OTOLOGICALS	-	-	-	1 885	2	6
S02A	ANTIINFECTIVES	-	-	-	725	2	-1
S02AA	Antiinfectives	-	-	-	725	2	-1
S02AA03	boric acid	-	-	-	705	2	-2
S02AA15	ciprofloxacin	-	-	-	20	3	19
S02B	CORTICOSTEROIDS	-	-	-	26	0	63
S02BA	Corticosteroids	-	-	-	26	0	63
S02BA08	fluocinolone acetonide	-	-	-	26	0	63
S02C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	-	-	-	1 021	3	11
S02CA	Corticosteroids and antiinfectives in combination	-	-	-	1 021	3	11
S02CA02	flumetasone and antiinfectives	-	-	-	94	3	-58
S02CA03	hydrocortisone and antiinfectives	-	-	-	427	3	13
S02CA05	fluocinolone acetonide and antiinfectives	-	-	-	500	3	58
S02D	OTHER OTOLOGICALS	-	-	-	114	1	-1
S02DA	Analgesics and anesthetics	-	-	-	114	1	-1

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
S02DA04	cinchocaine	-	-	-	114	1	-1
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	-	-	-	187	13	-3
S03C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	-	-	-	187	13	-3
S03CA	Corticosteroids and antiinfectives in combination	-	-	-	187	13	-3
S03CA04	hydrocortisone and antiinfectives	-	-	-	187	13	-3
<b>V</b>	<b>VARIOUS</b>	<b>0,18</b>	<b>44</b>	<b>-5</b>	<b>41 440</b>	<b>85</b>	<b>4</b>
V01	ALLERGENS	-	-	-	6 244	45	25
V01A	ALLERGENS	-	-	-	6 244	45	25
V01AA	Allergen extracts	-	-	-	6 244	45	25
V01AA02	grass pollen	-	-	-	1 067	0	26
V01AA03	house dust mites	-	-	-	52	24	4
V01AA05	tree pollen	-	-	-	4 645	51	24
V01AA07	insects	-	-	-	267	99	24
V01AA11	animals	-	-	-	212	77	62
V01AA20	various	-	-	-	1	100	-29
V03	ALL OTHER THERAPEUTIC PRODUCTS	0,18	44	-5	8 683	76	-7
V03A	ALL OTHER THERAPEUTIC PRODUCTS	0,18	44	-5	8 683	76	-7
V03AB	Antidotes	-	-	-	4 895	97	-10
V03AB14	protamine	-	-	-	317	100	26
V03AB15	naloxone	-	-	-	69	91	-74
V03AB17	methylthionium chloride	-	-	-	112	99	3
V03AB21	potassium iodide	-	-	-	130	22	-71
V03AB25	flumazenil	-	-	-	39	96	-51
V03AB33	hydroxocobalamin	-	-	-	197	99	24
V03AB34	fomepizole	-	-	-	79	99	-7
V03AB35	sugammadex	-	-	-	3 395	99	-1
V03AB37	idarucizumab	-	-	-	225	100	14
V03AB38	andexanet alfa	-	-	-	333	100	-21
V03AC	Iron chelating agents	-	-	-	1 035	7	2
V03AC01	deferoxamine	-	-	-	20	100	4
V03AC02	deferiprone	-	-	-	9	31	-
V03AC03	deferasirox	-	-	-	1 006	5	1

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia	0,12	17	-10	1 063	17	-14
V03AE01	polystyrene sulphonate	0,03	23	0	106	23	0
V03AE02	sevelamer	0,04	15	1	405	16	1
V03AE03	lanthanum carbonate	0,04	15	-32	459	16	-33
V03AE05	sucroferric oxyhydroxide	0,00	4	86	25	4	86
V03AE09	patiromer calcium	0,01	24	180	68	25	157
V03AF	Detoxifying agents for cytostatic treatment	0,06	94	6	1 690	93	3
V03AF01	mesna	-	-	-	459	100	2
V03AF02	dexrazoxane	0,00	100	58	216	100	63
V03AF03	calcium folinate	0,06	94	5	517	76	-17
V03AF07	rasburicase	0,00	100	25	469	99	13
V03AF10	sodium levofolinate	0,00	100	66	29	100	67
V04	DIAGNOSTIC AGENTS	-	-	-	868	92	-3
V04C	OTHER DIAGNOSTIC AGENTS	-	-	-	868	92	-3
V04CD	Tests for pituitary function	-	-	-	77	32	-28
V04CD01	metyrapone	-	-	-	77	32	-28
V04CF	Tuberculosis diagnostics	-	-	-	3	77	-53
V04CF01	tuberculin	-	-	-	3	77	-53
V04CL	Tests for allergic diseases	-	-	-	89	77	-1
V04CX	Other diagnostic agents	-	-	-	699	100	1
V04CX05	13C-urea	-	-	-	0	-	-100
V04CX06	hexaminolevulinate	-	-	-	699	100	1
V07	ALL OTHER NON-THERAPEUTIC PRODUCTS	-	-	-	2 907	92	-5
V07A	ALL OTHER NON-THERAPEUTIC PRODUCTS	-	-	-	2 907	92	-5
V07AB	Solvents and diluting agents, incl. irrigating solutions	-	-	-	2 907	92	-5
V08	CONTRAST MEDIA	-	-	-	22 728	98	6
V08A	X-RAY CONTRAST MEDIA, IODINATED	-	-	-	17 541	99	3
V08AA	Watersoluble, nephrotropic, high osmolar X-ray contrast media	-	-	-	125	100	6
V08AA01	diatrizoic acid	-	-	-	125	100	6
V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media	-	-	-	17 416	99	3

## Drug consumption in current year (Period 202101 - 202112)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
V08AB02	iohexol	-	-	-	14 129	99	5
V08AB07	ioversol	-	-	-	0	-	-100
V08AB09	iodixanol	-	-	-	1 102	97	4
V08AB10	iomeprol	-	-	-	2 186	99	-11
V08C	MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	-	-	-	5 115	96	19
V08CA	Paramagnetic contrast media	-	-	-	5 115	96	19
V08CA02	gadoteric acid	-	-	-	4 915	95	21
V08CA04	gadoteridol	-	-	-	4	83	-72
V08CA08	gadobenec acid	-	-	-	0	-	-100
V08CA09	gadobutrol	-	-	-	0	-	-100
V08CA10	gadoxetic acid	-	-	-	196	100	-5
V08D	ULTRASOUND CONTRAST MEDIA	-	-	-	72	99	3
V08DA	Ultrasound contrast media	-	-	-	72	99	3
V08DA01	microspheres of human albumin	-	-	-	1	100	-60
V08DA05	sulphur hexafluoride	-	-	-	72	99	5
V09	DIAGNOSTIC RADIOPHARMACEUTICALS	-	-	-	12	100	-78
V09C	RENAL SYSTEM	-	-	-	3	100	-83
V09CA	Technetium (99mTc) compounds	-	-	-	3	100	-83
V09CA03	technetium (99mTc) mertiatide	-	-	-	3	100	-83
V09D	HEPATIC AND RETICULO ENDOTHELIAL SYSTEM	-	-	-	9	100	-76
V09DB	Technetium (99mTc), particles and colloids	-	-	-	9	100	-76
V09DB01	technetium (99mTc) nanocolloid	-	-	-	9	100	-76

Hospital % Sales to hospitals and other health care units as a proportion (%) of the wholesale value

Change % is compared with equal period in previous year